[{"orgOrder":0,"company":"Bridge Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Undisclosed","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Anti-EGFR antibodies","moa":"EGFR","graph1":"Oncology","graph2":"IND Enabling","graph3":"Bridge Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bridge Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Bridge Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Celularity","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"CYNK-001","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Celularity","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Celularity \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Celularity \/ Not Applicable"},{"orgOrder":0,"company":"Dialectic Therapeutics","sponsor":"Cancer Prevention & Research Institute of Texas","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","date":"February 2020","year":"2020","type":"Funding","leadProduct":"DT2216","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Dialectic Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Dialectic Therapeutics \/ Cancer Prevention & Research Institute of Texas","highestDevelopmentStatusID":"5","companyTruncated":"Dialectic Therapeutics \/ Cancer Prevention & Research Institute of Texas"},{"orgOrder":0,"company":"Kleo Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"KP1237","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Kleo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Kleo Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Kleo Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Cotsiranib","moa":"TGF beta-1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Sirnaomics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Sirnaomics \/ Not Applicable"},{"orgOrder":0,"company":"Elicio Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"ELI-002","moa":"mKRAS","graph1":"Oncology","graph2":"IND Enabling","graph3":"Elicio Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Elicio Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Elicio Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Elicio Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"ELI-002","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Elicio Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Elicio Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Elicio Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Pacylex Pharmaceuticals","sponsor":"Canadian angel investors","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"CANADA","productType":"Small molecule","date":"March 2020","year":"2020","type":"Financing","leadProduct":"PCLX-001","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Pacylex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pacylex Pharmaceuticals \/ Canadian angel investors","highestDevelopmentStatusID":"5","companyTruncated":"Pacylex Pharmaceuticals \/ Canadian angel investors"},{"orgOrder":0,"company":"Amunix","sponsor":"Omega Funds","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"March 2020","year":"2020","type":"Series A Financing","leadProduct":"AMX-818","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Amunix","amount2":0.070000000000000007,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"Amunix \/ Omega Funds","highestDevelopmentStatusID":"5","companyTruncated":"Amunix \/ Omega Funds"},{"orgOrder":0,"company":"Numab Therapeutics","sponsor":"3SBio ","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Large molecule","date":"March 2020","year":"2020","type":"Series B Financing","leadProduct":"ND021","moa":"PD-L1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Numab Therapeutics","amount2":0.02,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"","sponsorNew":"Numab Therapeutics \/ 3SBio ","highestDevelopmentStatusID":"5","companyTruncated":"Numab Therapeutics \/ 3SBio "},{"orgOrder":0,"company":"Lonza Group","sponsor":"Triumvira Immunologics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Cell and Gene therapy","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"TAC01-HER2","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Lonza Group \/ Triumvira Immunologics","highestDevelopmentStatusID":"5","companyTruncated":"Lonza Group \/ Triumvira Immunologics"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Elicio Therapeutics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"ELI-002","moa":"KRAS","graph1":"Oncology","graph2":"IND Enabling","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"National Cancer Institute \/ Elicio Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"National Cancer Institute \/ Elicio Therapeutics"},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"TST001","moa":"CLDN18.2","graph1":"Oncology","graph2":"IND Enabling","graph3":"Transcenta Holding","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Transcenta Holding \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Transcenta Holding \/ Not Applicable"},{"orgOrder":0,"company":"Precigen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"PRGN-2009","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Precigen","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Precigen \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Precigen \/ Not Applicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Natural killer cells","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"INmune Bio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"INmune Bio \/ Not Applicable"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"EDIT-201","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Editas Medicine \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Editas Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Rubius Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"RTX-321","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Rubius Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Rubius Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Rubius Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"ZN-d5","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Zentalis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Zentalis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Zentalis Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Sapience Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Peptide","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"ST101","moa":"CCAAT\/enhancer binding protein beta","graph1":"Oncology","graph2":"IND Enabling","graph3":"Sapience Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Sapience Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Sapience Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"HJB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Humanized Claudin18.2 monoclonal antibody","moa":"Claudin 18.2","graph1":"Oncology","graph2":"IND Enabling","graph3":"HJB","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"HJB \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"HJB \/ Not Applicable"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"MB-104","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Mustang Bio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Mustang Bio \/ Not Applicable"},{"orgOrder":0,"company":"HiFiBiO Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"HFB301001","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"HiFiBiO Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"HiFiBiO Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"HiFiBiO Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"EDIT-201","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Editas Medicine \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Editas Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Kleo Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"KP1237","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Kleo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Kleo Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Kleo Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"BioInvent","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"BI-1808","moa":"TNF-1 beta","graph1":"Oncology","graph2":"IND Enabling","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"BioInvent \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"BioInvent \/ Not Applicable"},{"orgOrder":0,"company":"Hillstream BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Salinomycin","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hillstream BioPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Hillstream BioPharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Hillstream BioPharma \/ Not Applicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"AGENT-797","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Agenus \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Agenus \/ Not Applicable"},{"orgOrder":0,"company":"Brown University","sponsor":"Undisclosed","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","date":"June 2020","year":"2020","type":"Funding","leadProduct":"ONC212","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Brown University","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Brown University \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Brown University \/ Undisclosed"},{"orgOrder":0,"company":"Maverick Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"MVC-101","moa":"EGFR","graph1":"Oncology","graph2":"IND Enabling","graph3":"Maverick Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Maverick Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Maverick Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Neurotrope","sponsor":"BryoLogyx Inc","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"Bryostatin-1","moa":"PKC","graph1":"Oncology","graph2":"IND Enabling","graph3":"Neurotrope","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Neurotrope \/ BryoLogyx","highestDevelopmentStatusID":"5","companyTruncated":"Neurotrope \/ BryoLogyx"},{"orgOrder":0,"company":"City of Hope","sponsor":"Scopus BioPharma","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"June 2020","year":"2020","type":"Licensing Agreement","leadProduct":"CpG-STAT3siRNA","moa":"STAT3 protein","graph1":"Oncology","graph2":"IND Enabling","graph3":"City of Hope","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"City of Hope \/ Scopus BioPharma","highestDevelopmentStatusID":"5","companyTruncated":"City of Hope \/ Scopus BioPharma"},{"orgOrder":0,"company":"Curis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"CI-8993","moa":"VISTA","graph1":"Oncology","graph2":"IND Enabling","graph3":"Curis","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Curis \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Curis \/ Not Applicable"},{"orgOrder":0,"company":"GeneQuantum Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"JAPAN","productType":"Large molecule","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"GQ1001","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"GeneQuantum Healthcare","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"GeneQuantum Healthcare \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"GeneQuantum Healthcare \/ Not Applicable"},{"orgOrder":0,"company":"Bellicum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"BPX-603","moa":"MyD88\/CD40","graph1":"Oncology","graph2":"IND Enabling","graph3":"Bellicum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Bellicum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Bellicum Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Genocea","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"GEN-011","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Genocea","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Genocea \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Genocea \/ Not Applicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"INKmune","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"INmune Bio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"INmune Bio \/ Not Applicable"},{"orgOrder":0,"company":"Jounce Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"JTX-1811","moa":"CCR8","graph1":"Oncology","graph2":"IND Enabling","graph3":"Jounce Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Jounce Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Jounce Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Tizona Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"TTX-080","moa":"HLA-G","graph1":"Oncology","graph2":"IND Enabling","graph3":"Tizona Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Tizona Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Tizona Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Aptose Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"CG-806","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Aptose Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aptose Biosciences \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Aptose Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Amunix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"AMX-818","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Amunix","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Amunix \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Amunix \/ Not Applicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"TransCon IL-2 \u03b2\/\u03b3","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ascendis Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Ascendis Pharma \/ Not Applicable"},{"orgOrder":0,"company":"BioInvent","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"BI-1808","moa":"TNF-1B","graph1":"Oncology","graph2":"IND Enabling","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"BioInvent \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"BioInvent \/ Not Applicable"},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"FT819","moa":"CAR19 T Cell","graph1":"Oncology","graph2":"IND Enabling","graph3":"Fate Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Fate Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Fate Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"NeoImmuneTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Efineptakin alfa","moa":"IL-7","graph1":"Oncology","graph2":"IND Enabling","graph3":"NeoImmuneTech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"NeoImmuneTech \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"NeoImmuneTech \/ Not Applicable"},{"orgOrder":0,"company":"Genocea","sponsor":"Brookline Capital Markets","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"July 2020","year":"2020","type":"Private Placement","leadProduct":"GEN-011","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Genocea","amount2":0.080000000000000002,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Genocea \/ Brookline Capital Markets","highestDevelopmentStatusID":"5","companyTruncated":"Genocea \/ Brookline Capital Markets"},{"orgOrder":0,"company":"NeoImmuneTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Efineptakin alfa","moa":"IL-7","graph1":"Oncology","graph2":"IND Enabling","graph3":"NeoImmuneTech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"NeoImmuneTech \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"NeoImmuneTech \/ Not Applicable"},{"orgOrder":0,"company":"Bright Peak Therapeutics","sponsor":"Ridgeline Therapeutics Discovery","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"July 2020","year":"2020","type":"Series A Financing","leadProduct":"IL-2 conjugates","moa":"CD25 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Bright Peak Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Bright Peak Therapeutics \/ Ridgeline Therapeutics Discovery","highestDevelopmentStatusID":"5","companyTruncated":"Bright Peak Therapeutics \/ Ridgeline Therapeutics Discovery"},{"orgOrder":0,"company":"CytoImmune Therapeutics","sponsor":"Cytovia Therapeutics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"August 2020","year":"2020","type":"Acquisition","leadProduct":"CYT-101","moa":"Dual EGFR","graph1":"Oncology","graph2":"IND Enabling","graph3":"CytoImmune Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intracranial Injection","sponsorNew":"CytoImmune Therapeutics \/ Cytovia Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"CytoImmune Therapeutics \/ Cytovia Therapeutics"},{"orgOrder":0,"company":"Maverick Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"MVC-101","moa":"EGFR","graph1":"Oncology","graph2":"IND Enabling","graph3":"Maverick Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Maverick Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Maverick Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Maverick Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"MVC-101","moa":"EGFR","graph1":"Oncology","graph2":"IND Enabling","graph3":"Maverick Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Maverick Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Maverick Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"NeoImmuneTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Efineptakin alfa","moa":"IL-7","graph1":"Oncology","graph2":"IND Enabling","graph3":"NeoImmuneTech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"NeoImmuneTech \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"NeoImmuneTech \/ Not Applicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Natural killer cells","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"INmune Bio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"INmune Bio \/ Not Applicable"},{"orgOrder":0,"company":"Kleo Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"KP1237","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Kleo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Kleo Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Kleo Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"MorphoSys","sponsor":"I-Mab Biopharma","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"MOR210","moa":"Complement C5a receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"MorphoSys \/ I-Mab","highestDevelopmentStatusID":"5","companyTruncated":"MorphoSys \/ I-Mab"},{"orgOrder":0,"company":"Genocea","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"GEN-011","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Genocea","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Genocea \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Genocea \/ Not Applicable"},{"orgOrder":0,"company":"Athenex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"TCRT-ESO-A2","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Athenex","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Athenex \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Athenex \/ Not Applicable"},{"orgOrder":0,"company":"PharmaCyte Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Encapsulated Live Cells Converting Ifosamide","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"PharmaCyte Biotech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"PharmaCyte Biotech \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"PharmaCyte Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Aprea Therapeutics","sponsor":"Karolinska Development AB","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"APR-548","moa":"p53","graph1":"Oncology","graph2":"IND Enabling","graph3":"Aprea Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aprea Therapeutics \/ Karolinska Development AB","highestDevelopmentStatusID":"5","companyTruncated":"Aprea Therapeutics \/ Karolinska Development AB"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Axis Therapeutics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"TCRT-ESO-A2","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"PharmaEssentia \/ Axis Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"PharmaEssentia \/ Axis Therapeutics"},{"orgOrder":0,"company":"Aptorum","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","date":"October 2020","year":"2020","type":"Public Offering","leadProduct":"SACT-1","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Aptorum","amount2":0.01,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"","sponsorNew":"Aptorum \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"5","companyTruncated":"Aptorum \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Oxular","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"OXU-003","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Oxular","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Oxular \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Oxular \/ Not Applicable"},{"orgOrder":0,"company":"Axis Therapeutics","sponsor":"PharmaEssentia","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"TCRT-ESO-A2","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Axis Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Axis Therapeutics \/ PharmaEssentia","highestDevelopmentStatusID":"5","companyTruncated":"Axis Therapeutics \/ PharmaEssentia"},{"orgOrder":0,"company":"BioInvent","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"BI-1808","moa":"TNFR2 alpha","graph1":"Oncology","graph2":"IND Enabling","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"BioInvent \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"BioInvent \/ Not Applicable"},{"orgOrder":0,"company":"OS Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Vaccine","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"OST-HER2","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"OS Therapies","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"OS Therapies \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"OS Therapies \/ Not Applicable"},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Peptide","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"OPD5","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Oncopeptides","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Oncopeptides \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Oncopeptides \/ Not Applicable"},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Etigilimab","moa":"TIGIT","graph1":"Oncology","graph2":"IND Enabling","graph3":"Mereo BioPharma Group","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mereo BioPharma Group \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Mereo BioPharma Group \/ Not Applicable"},{"orgOrder":0,"company":"Focus Fund GP","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","date":"October 2020","year":"2020","type":"Partnership","leadProduct":"Cancer therapies","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Focus Fund GP","amount2":0.050000000000000003,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Focus Fund GP \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"5","companyTruncated":"Focus Fund GP \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"MorphoSys","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"MOR210","moa":"Complement C5a receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"I-Mab Biopharma \/ MorphoSys","highestDevelopmentStatusID":"5","companyTruncated":"I-Mab Biopharma \/ MorphoSys"},{"orgOrder":0,"company":"Rubius Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"RTX-321","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Rubius Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Rubius Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Rubius Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"177Lu-omburtamab-DTPA","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Y-mAbs Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Y-mAbs Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Y-mAbs Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"enGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"EG-70","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"enGene","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Injection","sponsorNew":"enGene \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"enGene \/ Not Applicable"},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"HPN601","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Harpoon Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Harpoon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Harpoon Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Affimed","sponsor":"Roivant Sciences","pharmaFlowCategory":"D","upfrontCash":"$60.0 million","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"November 2020","year":"2020","type":"Collaboration","leadProduct":"AFM32","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Affimed","amount2":2.0600000000000001,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":2.0600000000000001,"dosageForm":"","sponsorNew":"Affimed \/ Roivant Sciences","highestDevelopmentStatusID":"5","companyTruncated":"Affimed \/ Roivant Sciences"},{"orgOrder":0,"company":"OneThree Biotech","sponsor":"Jubilant Therapeutics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"November 2020","year":"2020","type":"Collaboration","leadProduct":"JBI-802","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"OneThree Biotech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"OneThree Biotech \/ Jubilant Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"OneThree Biotech \/ Jubilant Therapeutics"},{"orgOrder":0,"company":"Calithera Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"CB-668","moa":"IL4I1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Calithera Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"oral","sponsorNew":"Calithera Biosciences \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Calithera Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"HPN601","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Harpoon Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Harpoon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Harpoon Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"JW Therapeutics","sponsor":"Goldman Sachs","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"November 2020","year":"2020","type":"Public Offering","leadProduct":"Relmacabtagene autoleucel","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"JW Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"JW Therapeutics \/ Goldman Sachs","highestDevelopmentStatusID":"5","companyTruncated":"JW Therapeutics \/ Goldman Sachs"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Daratumumab","moa":"CD38","graph1":"Oncology","graph2":"IND Enabling","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"injection","sponsorNew":"Shanghai Henlius Biotech \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Shanghai Henlius Biotech \/ Not Applicable"},{"orgOrder":0,"company":"NeoImmuneTech","sponsor":"Genentech","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"IL-7","graph1":"Oncology","graph2":"IND Enabling","graph3":"NeoImmuneTech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"NeoImmuneTech \/ Genentech","highestDevelopmentStatusID":"5","companyTruncated":"NeoImmuneTech \/ Genentech"},{"orgOrder":0,"company":"Elicio Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Vaccine","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"ELI-002","moa":"mKRAS","graph1":"Oncology","graph2":"IND Enabling","graph3":"Elicio Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Elicio Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Elicio Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"ATA3271","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Atara Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Atara Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Atara Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"University of Michigan","sponsor":"Ascentage Pharma","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","date":"November 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"MDM2 protein","graph1":"Oncology","graph2":"IND Enabling","graph3":"University of Michigan","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"University of Michigan \/ Ascentage Pharma","highestDevelopmentStatusID":"5","companyTruncated":"University of Michigan \/ Ascentage Pharma"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Cotsiranib","moa":"TGF beta-1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Sirnaomics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Sirnaomics \/ Not Applicable"},{"orgOrder":0,"company":"Chordia Therapeutics","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"December 2020","year":"2020","type":"Collaboration","leadProduct":"CTX-177","moa":"MALT1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Chordia Therapeutics","amount2":0.51000000000000001,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.51000000000000001,"dosageForm":"Oral","sponsorNew":"Chordia Therapeutics \/ Ono Pharmaceutical","highestDevelopmentStatusID":"5","companyTruncated":"Chordia Therapeutics \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Surface Oncology","sponsor":"GSK","pharmaFlowCategory":"D","upfrontCash":"$85.0 million","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"December 2020","year":"2020","type":"Licensing Agreement","leadProduct":"SRF813","moa":"PVRIG","graph1":"Oncology","graph2":"IND Enabling","graph3":"Surface Oncology","amount2":0.81999999999999995,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.81999999999999995,"dosageForm":"","sponsorNew":"Surface Oncology \/ GlaxoSmithKline","highestDevelopmentStatusID":"5","companyTruncated":"Surface Oncology \/ GlaxoSmithKline"},{"orgOrder":0,"company":"Targovax","sponsor":"IOVaxis Therapeutics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Vaccine","date":"January 2021","year":"2021","type":"Licensing Agreement","leadProduct":"TG01","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Targovax","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Targovax \/ IOVaxis","highestDevelopmentStatusID":"5","companyTruncated":"Targovax \/ IOVaxis"},{"orgOrder":0,"company":"GX Acquisition","sponsor":"Celularity","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","date":"January 2021","year":"2021","type":"Merger","leadProduct":"CYNK-101","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"GX Acquisition","amount2":0.37,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.37,"dosageForm":"","sponsorNew":"GX Acquisition \/ Celularity","highestDevelopmentStatusID":"5","companyTruncated":"GX Acquisition \/ Celularity"},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Cormorant Asset Management","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"January 2021","year":"2021","type":"Series A Financing","leadProduct":"BMF-219","moa":"Irreversible menin","graph1":"Oncology","graph2":"IND Enabling","graph3":"Biomea Fusion","amount2":0.059999999999999998,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.059999999999999998,"dosageForm":"oral","sponsorNew":"Biomea Fusion \/ Cormorant Asset Management","highestDevelopmentStatusID":"5","companyTruncated":"Biomea Fusion \/ Cormorant Asset Management"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Daratumumab","moa":"CD38","graph1":"Oncology","graph2":"IND Enabling","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Henlius Biotech \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Shanghai Henlius Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"OS Therapies","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Vaccine","date":"January 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Attenuted Listeria monocytogene","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Ayala Pharmaceuticals \/ OS Therapies","highestDevelopmentStatusID":"5","companyTruncated":"Ayala Pharmaceuticals \/ OS Therapies"},{"orgOrder":0,"company":"TScan Therapeutics","sponsor":"BlackRock","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"January 2021","year":"2021","type":"Series C Financing","leadProduct":"TSC-100","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"TScan Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"TScan Therapeutics \/ BlackRock","highestDevelopmentStatusID":"5","companyTruncated":"TScan Therapeutics \/ BlackRock"},{"orgOrder":0,"company":"Scopus Biopharma","sponsor":"The Benchmark Company","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"January 2021","year":"2021","type":"Public Offering","leadProduct":"CO-sTiRNA","moa":"STAT3 protein","graph1":"Oncology","graph2":"IND Enabling","graph3":"Scopus Biopharma","amount2":0.01,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"","sponsorNew":"Scopus Biopharma \/ The Benchmark Company","highestDevelopmentStatusID":"5","companyTruncated":"Scopus Biopharma \/ The Benchmark Company"},{"orgOrder":0,"company":"Nuvalent","sponsor":"Deerfield Management","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"January 2021","year":"2021","type":"Series A Financing","leadProduct":"NUV-520","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Nuvalent","amount2":0.050000000000000003,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Nuvalent \/ Deerfield Management","highestDevelopmentStatusID":"5","companyTruncated":"Nuvalent \/ Deerfield Management"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Stealth cell","moa":"CD19","graph1":"Oncology","graph2":"IND Enabling","graph3":"Precision BioSciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Precision BioSciences \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Precision BioSciences \/ Not Applicable"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"ATYR2810","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"aTyr Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"aTyr Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Stealth cell","moa":"CD19","graph1":"Oncology","graph2":"IND Enabling","graph3":"Precision BioSciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Precision BioSciences \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Precision BioSciences \/ Not Applicable"},{"orgOrder":0,"company":"Samsung Biologics","sponsor":"National OncoVenture","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"EU101","moa":"4-1BB receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Samsung Biologics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Samsung Biologics \/ National OncoVenture","highestDevelopmentStatusID":"5","companyTruncated":"Samsung Biologics \/ National OncoVenture"},{"orgOrder":0,"company":"Vor Biopharma","sponsor":"Renaissance Capital","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"February 2021","year":"2021","type":"Public Offering","leadProduct":"Engineered hematopoietic stem cell therapy","moa":"CD33","graph1":"Oncology","graph2":"IND Enabling","graph3":"Vor Biopharma","amount2":0.14999999999999999,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.14999999999999999,"dosageForm":"","sponsorNew":"Vor Biopharma \/ Renaissance Capital","highestDevelopmentStatusID":"5","companyTruncated":"Vor Biopharma \/ Renaissance Capital"},{"orgOrder":0,"company":"Eutilex Inc","sponsor":"Samsung Biologics","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"EU101","moa":"4-1BB receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Eutilex Inc","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Eutilex Inc \/ Samsung Biologics","highestDevelopmentStatusID":"5","companyTruncated":"Eutilex Inc \/ Samsung Biologics"},{"orgOrder":0,"company":"BITT","sponsor":"BeiGene","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"February 2021","year":"2021","type":"Collaboration","leadProduct":"BITR2101","moa":"TNFR2","graph1":"Oncology","graph2":"IND Enabling","graph3":"BITT","amount2":0.13,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.13,"dosageForm":"","sponsorNew":"BITT \/ BeiGene","highestDevelopmentStatusID":"5","companyTruncated":"BITT \/ BeiGene"},{"orgOrder":0,"company":"Merck Group","sponsor":"Day One Biopharmaceuticals","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"February 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Pimasertib","moa":"MEK 1\/2","graph1":"Oncology","graph2":"IND Enabling","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"oral","sponsorNew":"Merck Group \/ Day One Biopharmaceuticals","highestDevelopmentStatusID":"5","companyTruncated":"Merck Group \/ Day One Biopharmaceuticals"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Propella Therapeutics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"February 2021","year":"2021","type":"Partnership","leadProduct":"Abiraterone decanoate","moa":"Androgen receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"National Cancer Institute \/ Propella Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"National Cancer Institute \/ Propella Therapeutics"},{"orgOrder":0,"company":"Mateon Therapeutics","sponsor":"Oceanpine Capital","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"February 2021","year":"2021","type":"Series A Financing","leadProduct":"TT-702","moa":"A2BR","graph1":"Oncology","graph2":"IND Enabling","graph3":"Mateon Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Mateon Therapeutics \/ Oceanpine Capital","highestDevelopmentStatusID":"5","companyTruncated":"Mateon Therapeutics \/ Oceanpine Capital"},{"orgOrder":0,"company":"Cullgen","sponsor":"3E Bioventures","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"February 2021","year":"2021","type":"Series B Financing","leadProduct":"CG001419","moa":"TRK protein","graph1":"Oncology","graph2":"IND Enabling","graph3":"Cullgen","amount2":0.050000000000000003,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Cullgen \/ 3E Bioventures","highestDevelopmentStatusID":"5","companyTruncated":"Cullgen \/ 3E Bioventures"},{"orgOrder":0,"company":"Presage Biosciences","sponsor":"Labcorp","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","date":"March 2021","year":"2021","type":"Financing","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Presage Biosciences","amount2":0.01,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Intratumoral Injection","sponsorNew":"Presage Biosciences \/ LabCorp Venture Fund","highestDevelopmentStatusID":"5","companyTruncated":"Presage Biosciences \/ LabCorp Venture Fund"},{"orgOrder":0,"company":"Teon Therapeutics","sponsor":"Cancer Research","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"March 2021","year":"2021","type":"Collaboration","leadProduct":"TT-702","moa":"A2BR","graph1":"Oncology","graph2":"IND Enabling","graph3":"Teon Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Teon Therapeutics \/ Cancer Research UK","highestDevelopmentStatusID":"5","companyTruncated":"Teon Therapeutics \/ Cancer Research UK"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Surface Oncology","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"March 2021","year":"2021","type":"Collaboration","leadProduct":"Pembrolizumab","moa":"IL-27","graph1":"Oncology","graph2":"IND Enabling","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Merck & Co \/ Surface Oncology","highestDevelopmentStatusID":"5","companyTruncated":"Merck & Co \/ Surface Oncology"},{"orgOrder":0,"company":"KBI Biopharma","sponsor":"BITT","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"March 2021","year":"2021","type":"Agreement","leadProduct":"BITR2101","moa":"TNFR2","graph1":"Oncology","graph2":"IND Enabling","graph3":"KBI Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"KBI Biopharma \/ Boston Immune Technologies and Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"KBI Biopharma \/ Boston Immune Technologies and Therapeutics"},{"orgOrder":0,"company":"QureBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Q-1802","moa":"PD-L1","graph1":"Oncology","graph2":"IND Enabling","graph3":"QureBio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"QureBio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"QureBio \/ Not Applicable"},{"orgOrder":0,"company":"Dialectic Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"DT2216","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Dialectic Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Dialectic Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Dialectic Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Tarus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"TT-10","moa":"Adenosine A2A receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Tarus Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tarus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Tarus Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Ikena Oncology","sponsor":"Jefferies","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"March 2021","year":"2021","type":"Public Offering","leadProduct":"IK-930","moa":"Transcription Factor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ikena Oncology","amount2":0.13,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.13,"dosageForm":"Oral","sponsorNew":"Ikena Oncology \/ Jefferies","highestDevelopmentStatusID":"5","companyTruncated":"Ikena Oncology \/ Jefferies"},{"orgOrder":0,"company":"Pyxis Oncology","sponsor":"Arix Bioscience Plc","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"March 2021","year":"2021","type":"Series B Financing","leadProduct":"PYX-201","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Pyxis Oncology","amount2":0.14999999999999999,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.14999999999999999,"dosageForm":"","sponsorNew":"Pyxis Oncology \/ Arix Bioscience","highestDevelopmentStatusID":"5","companyTruncated":"Pyxis Oncology \/ Arix Bioscience"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"ABL111","moa":"CD137 antigen","graph1":"Oncology","graph2":"IND Enabling","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"I-Mab Biopharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"I-Mab Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Columbia University","sponsor":"Ayala Pharmaceuticals","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","date":"April 2021","year":"2021","type":"Agreement","leadProduct":"ADXS-504","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Columbia University","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Columbia University \/ Advaxis","highestDevelopmentStatusID":"5","companyTruncated":"Columbia University \/ Advaxis"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Akamis Bio","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"April 2021","year":"2021","type":"Collaboration","leadProduct":"NG-641","moa":"AP\/CD3","graph1":"Oncology","graph2":"IND Enabling","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Bristol Myers Squibb \/ PsiOxus Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Bristol Myers Squibb \/ PsiOxus Therapeutics"},{"orgOrder":0,"company":"CytoImmune Therapeutics","sponsor":"City of Hope","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"April 2021","year":"2021","type":"Licensing Agreement","leadProduct":"CYTO NK-203","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"CytoImmune Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"CytoImmune Therapeutics \/ City of Hope","highestDevelopmentStatusID":"5","companyTruncated":"CytoImmune Therapeutics \/ City of Hope"},{"orgOrder":0,"company":"GSK","sponsor":"Zentalis Pharmaceuticals","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"April 2021","year":"2021","type":"Collaboration","leadProduct":"Niraparib tosylate","moa":"WEE1","graph1":"Oncology","graph2":"IND Enabling","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"GSK \/ Zentalis Pharmaceuticals","highestDevelopmentStatusID":"5","companyTruncated":"GSK \/ Zentalis Pharmaceuticals"},{"orgOrder":0,"company":"Merck & Co","sponsor":"TILT Biotherapeutics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"April 2021","year":"2021","type":"Collaboration","leadProduct":"Pembrolizumab","moa":"TNF alpha","graph1":"Oncology","graph2":"IND Enabling","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Merck & Co \/ TILT Biotherapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Merck & Co \/ TILT Biotherapeutics"},{"orgOrder":0,"company":"Lonza Group","sponsor":"aTyr Pharma","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"April 2021","year":"2021","type":"Partnership","leadProduct":"ATYR2810","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Lonza Group \/ aTyr Pharma","highestDevelopmentStatusID":"5","companyTruncated":"Lonza Group \/ aTyr Pharma"},{"orgOrder":0,"company":"Teon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"TT-702","moa":"Adenosine A2B receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Teon Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Teon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Teon Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Nammi Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"QXL138AM","moa":"CD138","graph1":"Oncology","graph2":"IND Enabling","graph3":"Nammi Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Nammi Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Nammi Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Tachyon Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"TACH101","moa":"KDM4 histone demethylase","graph1":"Oncology","graph2":"IND Enabling","graph3":"Tachyon Technologies","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Tachyon Technologies \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Tachyon Technologies \/ Not Applicable"},{"orgOrder":0,"company":"Akamis Bio","sponsor":"Bluebird Bio","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Anti-EGFR CAR-T therapy","moa":"EGFR","graph1":"Oncology","graph2":"IND Enabling","graph3":"Akamis Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Akamis Bio \/ BluebirdBio","highestDevelopmentStatusID":"5","companyTruncated":"Akamis Bio \/ BluebirdBio"},{"orgOrder":0,"company":"Peptron","sponsor":"Qilu Pharmaceutical","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"April 2021","year":"2021","type":"Licensing Agreement","leadProduct":"PAb001-ADC","moa":"MUC1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Peptron","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Peptron \/ Qilu Pharmaceutical","highestDevelopmentStatusID":"5","companyTruncated":"Peptron \/ Qilu Pharmaceutical"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Merck & Co","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"April 2021","year":"2021","type":"Collaboration","leadProduct":"Cytokine derivative therapeutics","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Sutro Biopharma","amount2":0.02,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"","sponsorNew":"Sutro Biopharma \/ Merck","highestDevelopmentStatusID":"5","companyTruncated":"Sutro Biopharma \/ Merck"},{"orgOrder":0,"company":"OS Therapies","sponsor":"Noble Capital Markets","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Vaccine","date":"April 2021","year":"2021","type":"Series A Financing","leadProduct":"Attenuted Listeria monocytogene","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"OS Therapies","amount2":0.01,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"","sponsorNew":"OS Therapies \/ Noble Capital Markets","highestDevelopmentStatusID":"5","companyTruncated":"OS Therapies \/ Noble Capital Markets"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"OS Therapies","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Vaccine","date":"April 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Attenuted Listeria monocytogene","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Ayala Pharmaceuticals \/ OS Therapies","highestDevelopmentStatusID":"5","companyTruncated":"Ayala Pharmaceuticals \/ OS Therapies"},{"orgOrder":0,"company":"ProBioGen","sponsor":"Asher Bio","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"April 2021","year":"2021","type":"Collaboration","leadProduct":"AB248","moa":"IL-2","graph1":"Oncology","graph2":"IND Enabling","graph3":"ProBioGen","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"ProBioGen \/ Asher Bio","highestDevelopmentStatusID":"5","companyTruncated":"ProBioGen \/ Asher Bio"},{"orgOrder":0,"company":"Anixa Biosciences","sponsor":"Moffitt Cancer Center","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Chimeric Antigen Receptor-T cell therapy","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Anixa Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Anixa Biosciences \/ Moffitt Cancer Center","highestDevelopmentStatusID":"5","companyTruncated":"Anixa Biosciences \/ Moffitt Cancer Center"},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"TST005","moa":"TGF-beta","graph1":"Oncology","graph2":"IND Enabling","graph3":"Transcenta Holding","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Transcenta Holding \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Transcenta Holding \/ Not Applicable"},{"orgOrder":0,"company":"Pyxis Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"PYX-201","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Pyxis Oncology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Pyxis Oncology \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Pyxis Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Tarus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"TT-4","moa":"Adenosine A2B receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Tarus Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tarus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Tarus Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"NKX019","moa":"CD19","graph1":"Oncology","graph2":"IND Enabling","graph3":"Nkarta Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Nkarta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Nkarta Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Vor Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Engineered hematopoietic stem cell therapy","moa":"CD33","graph1":"Oncology","graph2":"IND Enabling","graph3":"Vor Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Vor Biopharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Vor Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Checkmate Pharmaceuticals","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"May 2021","year":"2021","type":"Collaboration","leadProduct":"Cemiplimab","moa":"TLR9","graph1":"Oncology","graph2":"IND Enabling","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Checkmate Pharmaceuticals","highestDevelopmentStatusID":"5","companyTruncated":"Regeneron Pharmaceuticals \/ Checkmate Pharmaceuticals"},{"orgOrder":0,"company":"Codiak BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"exoASO-STAT6","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Codiak BioSciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Codiak BioSciences \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Codiak BioSciences \/ Not Applicable"},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"JAB-21822","moa":"KRAS G12C","graph1":"Oncology","graph2":"IND Enabling","graph3":"Jacobio Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Jacobio Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Jacobio Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Kahr Medical","sponsor":"Cancer Focus Fund","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"May 2021","year":"2021","type":"Funding","leadProduct":"Azacytidine","moa":"CD47x41BB","graph1":"Oncology","graph2":"IND Enabling","graph3":"Kahr Medical","amount2":0.01,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"Kahr Medical \/ Cancer Focus Fund","highestDevelopmentStatusID":"5","companyTruncated":"Kahr Medical \/ Cancer Focus Fund"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Cryopreserved m-ceNK cells","moa":"IL-15","graph1":"Oncology","graph2":"IND Enabling","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"ImmunityBio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"ImmunityBio \/ Not Applicable"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Cryopreserved m-ceNK cells","moa":"IL-15","graph1":"Oncology","graph2":"IND Enabling","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"ImmunityBio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"ImmunityBio \/ Not Applicable"},{"orgOrder":0,"company":"GammaDelta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"GDX012","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"GammaDelta Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"GammaDelta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"GammaDelta Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Tarus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"TT-4","moa":"Adenosine A2B receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Tarus Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tarus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Tarus Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Merck Group","sponsor":"Immutep","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"June 2021","year":"2021","type":"Collaboration","leadProduct":"Eftilagimod Alpha","moa":"APC","graph1":"Oncology","graph2":"IND Enabling","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck Group \/ Immutep","highestDevelopmentStatusID":"5","companyTruncated":"Merck Group \/ Immutep"},{"orgOrder":0,"company":"Kineta","sponsor":"Cheongbo Industrial","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"June 2021","year":"2021","type":"Financing","leadProduct":"KVA12.1","moa":"VISTA","graph1":"Oncology","graph2":"IND Enabling","graph3":"Kineta","amount2":0.029999999999999999,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Kineta \/ Cheongbo Industrial","highestDevelopmentStatusID":"5","companyTruncated":"Kineta \/ Cheongbo Industrial"},{"orgOrder":0,"company":"Bright Peak Therapeutics","sponsor":"RA Capital","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"June 2021","year":"2021","type":"Series B Financing","leadProduct":"BPT-143","moa":"IL-2 receptor alpha","graph1":"Oncology","graph2":"IND Enabling","graph3":"Bright Peak Therapeutics","amount2":0.11,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.11,"dosageForm":"","sponsorNew":"Bright Peak Therapeutics \/ RA Capital","highestDevelopmentStatusID":"5","companyTruncated":"Bright Peak Therapeutics \/ RA Capital"},{"orgOrder":0,"company":"Jounce Therapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","upfrontCash":"$85.0 million","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"June 2021","year":"2021","type":"Licensing Agreement","leadProduct":"JTX-1811","moa":"CCR8","graph1":"Oncology","graph2":"IND Enabling","graph3":"Jounce Therapeutics","amount2":0.81000000000000005,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.81000000000000005,"dosageForm":"","sponsorNew":"Jounce Therapeutics \/ Gilead Sciences","highestDevelopmentStatusID":"5","companyTruncated":"Jounce Therapeutics \/ Gilead Sciences"},{"orgOrder":0,"company":"HiFiBiO Therapeutics","sponsor":"Mirae Asset Financial Group","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"June 2021","year":"2021","type":"Series D Financing","leadProduct":"HFB200301","moa":"Anti-TNFR2","graph1":"Oncology","graph2":"IND Enabling","graph3":"HiFiBiO Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"HiFiBiO Therapeutics \/ Mirae Asset Financial Group","highestDevelopmentStatusID":"5","companyTruncated":"HiFiBiO Therapeutics \/ Mirae Asset Financial Group"},{"orgOrder":0,"company":"Biovaxys","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Vaccine","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"BVX-0918A","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Biovaxys","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biovaxys \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Biovaxys \/ Not Applicable"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"CT120","moa":"CD19\/CD22","graph1":"Oncology","graph2":"IND Enabling","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"IASO Bio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"IASO Bio \/ Not Applicable"},{"orgOrder":0,"company":"TILT Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"TNF-alpha","graph1":"Oncology","graph2":"IND Enabling","graph3":"TILT Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"TILT Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"TILT Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Aleta Biotherapeutics","sponsor":"Cancer Research","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"June 2021","year":"2021","type":"Collaboration","leadProduct":"ALETA-001","moa":"CD20","graph1":"Oncology","graph2":"IND Enabling","graph3":"Aleta Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Aleta Biotherapeutics \/ Cancer Research UK","highestDevelopmentStatusID":"5","companyTruncated":"Aleta Biotherapeutics \/ Cancer Research UK"},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"CLN-619","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Cullinan Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Cullinan Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Cullinan Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Merck & Co","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"CT120","moa":"CD19\/CD22","graph1":"Oncology","graph2":"IND Enabling","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"IASO Bio \/ Merck","highestDevelopmentStatusID":"5","companyTruncated":"IASO Bio \/ Merck"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"BridgeBio Pharma","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"July 2021","year":"2021","type":"Collaboration","leadProduct":"BBP-398","moa":"SHP2","graph1":"Oncology","graph2":"IND Enabling","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bristol Myers Squibb \/ BridgeBio","highestDevelopmentStatusID":"5","companyTruncated":"Bristol Myers Squibb \/ BridgeBio"},{"orgOrder":0,"company":"Kineta","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"KVA12.1","moa":"VISTA","graph1":"Oncology","graph2":"IND Enabling","graph3":"Kineta","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Kineta \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Kineta \/ Not Applicable"},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Actinium-225-Vofatamab","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Fusion Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Fusion Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Fusion Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Allogeneic gamma delta T cell","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Kiromic BioPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Kiromic BioPharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Kiromic BioPharma \/ Not Applicable"},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"JAB-21822","moa":"KRAS G12C","graph1":"Oncology","graph2":"IND Enabling","graph3":"Jacobio Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Jacobio Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Jacobio Pharma \/ Not Applicable"},{"orgOrder":0,"company":"T-knife","sponsor":"Fidelity Management & Research Company, LLC","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"August 2021","year":"2021","type":"Series B Financing","leadProduct":"TK-8001","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"T-knife","amount2":0.11,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.11,"dosageForm":"","sponsorNew":"T-knife \/ Fidelity Management & Research Company, LLC","highestDevelopmentStatusID":"5","companyTruncated":"T-knife \/ Fidelity Management & Research Company, LLC"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"CT120","moa":"CD19","graph1":"Oncology","graph2":"IND Enabling","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"IASO Bio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"IASO Bio \/ Not Applicable"},{"orgOrder":0,"company":"City of Hope","sponsor":"Calidi Biotherapeutics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"August 2021","year":"2021","type":"Collaboration","leadProduct":"Allogeneic Neural Stem Cell","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"City of Hope","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"City of Hope \/ Calidi Biotherapeutics","highestDevelopmentStatusID":"5","companyTruncated":"City of Hope \/ Calidi Biotherapeutics"},{"orgOrder":0,"company":"Puerto Rico Science Technology and Research Trust","sponsor":"Revive Therapeutics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"August 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Mushroom Ganoderma Lucidum Compounds","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Puerto Rico Science Technology and Research Trust","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Puerto Rico Science Technology and Research Trust \/ Revive Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Puerto Rico Science Technology and Research Trust \/ Revive Therapeutics"},{"orgOrder":0,"company":"PharmaCyte Biotech","sponsor":"H.C. Wainwright","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"August 2021","year":"2021","type":"Public Offering","leadProduct":"Encapsulated Live Cells","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"PharmaCyte Biotech","amount2":0.070000000000000007,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"PharmaCyte Biotech \/ H.C. Wainwright","highestDevelopmentStatusID":"5","companyTruncated":"PharmaCyte Biotech \/ H.C. Wainwright"},{"orgOrder":0,"company":"PharmaCyte Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"August 2021","year":"2021","type":"Public Offering","leadProduct":"Encapsulated Live Cells","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"PharmaCyte Biotech","amount2":0.089999999999999997,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"PharmaCyte Biotech \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"PharmaCyte Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"AS1411","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Qualigen Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Qualigen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Qualigen Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Laekna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Afuresertib","moa":"Pan-AKT","graph1":"Oncology","graph2":"IND Enabling","graph3":"Laekna Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Laekna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Laekna Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"iPSC-Derived Immunotherapy","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Therapeutic Solutions \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Therapeutic Solutions \/ Not Applicable"},{"orgOrder":0,"company":"HUYA Bioscience International","sponsor":"Genhouse Bio","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"HBI-2376","moa":"SHP2 Allosteric","graph1":"Oncology","graph2":"IND Enabling","graph3":"HUYA Bioscience International","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"HUYA Bioscience International \/ Genhouse Bio","highestDevelopmentStatusID":"5","companyTruncated":"HUYA Bioscience International \/ Genhouse Bio"},{"orgOrder":0,"company":"GeneQuantum Healthcare","sponsor":"BrighGene Biomedical","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2021","year":"2021","type":"Collaboration","leadProduct":"GQ1007","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"GeneQuantum Healthcare","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"GeneQuantum Healthcare \/ BrighGene Biomedical","highestDevelopmentStatusID":"5","companyTruncated":"GeneQuantum Healthcare \/ BrighGene Biomedical"},{"orgOrder":0,"company":"Asher Biotherapeutics","sponsor":"Wellington Management Company","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2021","year":"2021","type":"Series B Financing","leadProduct":"AB248","moa":"IL-2 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Asher Biotherapeutics","amount2":0.11,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.11,"dosageForm":"","sponsorNew":"Asher Biotherapeutics \/ Wellington Management Company","highestDevelopmentStatusID":"5","companyTruncated":"Asher Biotherapeutics \/ Wellington Management Company"},{"orgOrder":0,"company":"ONK Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"ONKT102","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"ONK Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"ONK Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"ONK Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"TransCon IL-2 \u03b2\/\u03b3","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Ascendis Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Ascendis Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"RMC-6291","moa":"KRASG12C","graph1":"Oncology","graph2":"IND Enabling","graph3":"Revolution Medicines","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Revolution Medicines \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Revolution Medicines \/ Not Applicable"},{"orgOrder":0,"company":"Pyxis Oncology","sponsor":"The University of Chicago","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2021","year":"2021","type":"Public Offering","leadProduct":"PYX-201","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Pyxis Oncology","amount2":0.10000000000000001,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Pyxis Oncology \/ The University of Chicago","highestDevelopmentStatusID":"5","companyTruncated":"Pyxis Oncology \/ The University of Chicago"},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"AB8939","moa":"Tubulin","graph1":"Oncology","graph2":"IND Enabling","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"AB Science \/ Not Applicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Ifenprodil Tartrate","moa":"GluN2B-NMDA receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Algernon Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"NTLA-5001","moa":"WT1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Intellia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Intellia Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"177Lu-PNT2004","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Point Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Point Biopharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Point Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Bexion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Saposin C","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Bexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bexion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Bexion Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"RMC-6291","moa":"KRASG12C","graph1":"Oncology","graph2":"IND Enabling","graph3":"Revolution Medicines","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Revolution Medicines \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Revolution Medicines \/ Not Applicable"},{"orgOrder":0,"company":"Humedix","sponsor":"Kineta","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"October 2021","year":"2021","type":"Partnership","leadProduct":"KVA12.1","moa":"VISTA","graph1":"Oncology","graph2":"IND Enabling","graph3":"Humedix","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Humedix \/ Kineta","highestDevelopmentStatusID":"5","companyTruncated":"Humedix \/ Kineta"},{"orgOrder":0,"company":"Abalos Therapeutics","sponsor":"Seventure Partners","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"October 2021","year":"2021","type":"Series A Financing","leadProduct":"Arenavirus-based Drug Candidates","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Abalos Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Abalos Therapeutics \/ Seventure Partners","highestDevelopmentStatusID":"5","companyTruncated":"Abalos Therapeutics \/ Seventure Partners"},{"orgOrder":0,"company":"Mosaic ImmunoEngineering","sponsor":"University of California San Diego","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"October 2021","year":"2021","type":"Licensing Agreement","leadProduct":"MIE-101","moa":"TLR","graph1":"Oncology","graph2":"IND Enabling","graph3":"Mosaic ImmunoEngineering","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral","sponsorNew":"Mosaic ImmunoEngineering \/ University of California San Diego","highestDevelopmentStatusID":"5","companyTruncated":"Mosaic ImmunoEngineering \/ University of California San Diego"},{"orgOrder":0,"company":"iOmx Therapeutics","sponsor":"Athos Service","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"October 2021","year":"2021","type":"Series B Financing","leadProduct":"IMT-07","moa":"SIK3 kinase","graph1":"Oncology","graph2":"IND Enabling","graph3":"iOmx Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"iOmx Therapeutics \/ Athos Service","highestDevelopmentStatusID":"5","companyTruncated":"iOmx Therapeutics \/ Athos Service"},{"orgOrder":0,"company":"Aurigene","sponsor":"Exelixis","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"October 2021","year":"2021","type":"Licensing Agreement","leadProduct":"XL114","moa":"CBM","graph1":"Oncology","graph2":"IND Enabling","graph3":"Aurigene","amount2":0.02,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"","sponsorNew":"Aurigene \/ Exelixis","highestDevelopmentStatusID":"5","companyTruncated":"Aurigene \/ Exelixis"},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"TYK","graph1":"Oncology","graph2":"IND Enabling","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"AB Science \/ Not Applicable"},{"orgOrder":0,"company":"Boan Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"BA1105","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Boan Biotech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Boan Biotech \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Boan Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Amunix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"AMX-818","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Amunix","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Amunix \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Amunix \/ Not Applicable"},{"orgOrder":0,"company":"Ikena Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"IK-930","moa":"TEAD","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ikena Oncology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ikena Oncology \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Ikena Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Sofie Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"[68Ga]FAPI-46","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Sofie Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Sofie Biosciences \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Sofie Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"October 2021","year":"2021","type":"Collaboration","leadProduct":"Datopotamab Deruxtecan","moa":"Trop2","graph1":"Oncology","graph2":"IND Enabling","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"5","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"GDA-201","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Gamida Cell","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Gamida Cell \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Gamida Cell \/ Not Applicable"},{"orgOrder":0,"company":"OS Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Vaccine","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Attenuted Listeria Monocytogene","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"OS Therapies","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"OS Therapies \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"OS Therapies \/ Not Applicable"},{"orgOrder":0,"company":"Antiva Biosciences","sponsor":"Adjuvant Capital","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"November 2021","year":"2021","type":"Series D Financing","leadProduct":"ABI-2280","moa":"HPV replication","graph1":"Oncology","graph2":"IND Enabling","graph3":"Antiva Biosciences","amount2":0.029999999999999999,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Antiva Biosciences \/ Adjuvant Capital","highestDevelopmentStatusID":"5","companyTruncated":"Antiva Biosciences \/ Adjuvant Capital"},{"orgOrder":0,"company":"IMPACT Therapeutics, Inc","sponsor":"Burning Rock Dx","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"November 2021","year":"2021","type":"Collaboration","leadProduct":"IMP9064","moa":"ATR","graph1":"Oncology","graph2":"IND Enabling","graph3":"IMPACT Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"IMPACT Therapeutics, Inc \/ Burning Rock Biotech Limited","highestDevelopmentStatusID":"5","companyTruncated":"IMPACT Therapeutics, Inc \/ Burning Rock Biotech Limited"},{"orgOrder":0,"company":"Celcuity","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"November 2021","year":"2021","type":"Collaboration","leadProduct":"Gedatolisib","moa":"Pan-PI3K class I","graph1":"Oncology","graph2":"IND Enabling","graph3":"Celcuity","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Celcuity \/ Pfizer","highestDevelopmentStatusID":"5","companyTruncated":"Celcuity \/ Pfizer"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"October 2021","year":"2021","type":"Collaboration","leadProduct":"Adagrasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"IND Enabling","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mirati Therapeutics \/ Sanofi","highestDevelopmentStatusID":"5","companyTruncated":"Mirati Therapeutics \/ Sanofi"},{"orgOrder":0,"company":"Ivy Brain Tumor Center","sponsor":"GSK","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"October 2021","year":"2021","type":"Collaboration","leadProduct":"Niraparib Tosylate","moa":"PARP","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ivy Brain Tumor Center","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ivy Brain Tumor Center \/ GSK","highestDevelopmentStatusID":"5","companyTruncated":"Ivy Brain Tumor Center \/ GSK"},{"orgOrder":0,"company":"Mosaic ImmunoEngineering","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"MIE-101","moa":"TLR","graph1":"Oncology","graph2":"IND Enabling","graph3":"Mosaic ImmunoEngineering","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral","sponsorNew":"Mosaic ImmunoEngineering \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Mosaic ImmunoEngineering \/ Not Applicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Onatasertib","moa":"mTORC1\/2","graph1":"Oncology","graph2":"IND Enabling","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Antengene \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Antengene \/ Not Applicable"},{"orgOrder":0,"company":"Palleon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Bi-Sialidase","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Palleon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Palleon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Palleon Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"AB8939","moa":"Tubulin","graph1":"Oncology","graph2":"IND Enabling","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"AB Science \/ Not Applicable"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"CT120","moa":"CD19","graph1":"Oncology","graph2":"IND Enabling","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"IASO Bio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"IASO Bio \/ Not Applicable"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Leucid Bio","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"December 2021","year":"2021","type":"Collaboration","leadProduct":"Autologous CAR-T Cells","moa":"NKG2D receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Lonza Group \/ Leucid Bio","highestDevelopmentStatusID":"5","companyTruncated":"Lonza Group \/ Leucid Bio"},{"orgOrder":0,"company":"Avidea Technologies","sponsor":"Barinthus Biotherapeutics","pharmaFlowCategory":"D","upfrontCash":"$12.5 million","therapeuticArea":"Oncology","country":"","productType":"Vaccine","date":"December 2021","year":"2021","type":"Acquisition","leadProduct":"SNAPvax Cancer Vaccine","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Avidea Technologies","amount2":0.040000000000000001,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"Intravenous","sponsorNew":"Avidea Technologies \/ Vaccitech plc","highestDevelopmentStatusID":"5","companyTruncated":"Avidea Technologies \/ Vaccitech plc"},{"orgOrder":0,"company":"Senti Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"SENTI-202","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Senti Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Senti Biosciences \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Senti Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Senti Biosciences","sponsor":"Dynamics Special Purpose Corp","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"December 2021","year":"2021","type":"Agreement","leadProduct":"SENTI-202","moa":"CD33","graph1":"Oncology","graph2":"IND Enabling","graph3":"Senti Biosciences","amount2":0.59999999999999998,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.59999999999999998,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Senti Biosciences \/ Dynamics Special Purpose Corp","highestDevelopmentStatusID":"5","companyTruncated":"Senti Biosciences \/ Dynamics Special Purpose Corp"},{"orgOrder":0,"company":"Amunix","sponsor":"Sanofi","pharmaFlowCategory":"D","upfrontCash":"$1,000.0 million","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"December 2021","year":"2021","type":"Acquisition","leadProduct":"AMX-818","moa":"Dysregulated protease","graph1":"Oncology","graph2":"IND Enabling","graph3":"Amunix","amount2":1.23,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":1.23,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Amunix \/ Sanofi","highestDevelopmentStatusID":"5","companyTruncated":"Amunix \/ Sanofi"},{"orgOrder":0,"company":"ONK Therapeutics","sponsor":"Acorn Bioventures","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"January 2022","year":"2022","type":"Series A Financing","leadProduct":"ONKT102","moa":"CD38","graph1":"Oncology","graph2":"IND Enabling","graph3":"ONK Therapeutics","amount2":0.02,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"","sponsorNew":"ONK Therapeutics \/ Acorn Bioventures","highestDevelopmentStatusID":"5","companyTruncated":"ONK Therapeutics \/ Acorn Bioventures"},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"NiKang Therapeutics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"January 2022","year":"2022","type":"Collaboration","leadProduct":"NKT2152","moa":"HIF-2 alpha","graph1":"Oncology","graph2":"IND Enabling","graph3":"Aveo Oncology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aveo Oncology \/ NiKang Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Aveo Oncology \/ NiKang Therapeutics"},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"RMC-6291","moa":"KRASG12C","graph1":"Oncology","graph2":"IND Enabling","graph3":"Revolution Medicines","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Revolution Medicines \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Revolution Medicines \/ Not Applicable"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"IMM-1-104","moa":"MEK","graph1":"Oncology","graph2":"IND Enabling","graph3":"Immuneering Corporation","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Immuneering Corporation \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Immuneering Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Laekna Therapeutics","sponsor":"Innovent Biologics","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Afuresertib","moa":"Pan-AKT kinase","graph1":"Oncology","graph2":"IND Enabling","graph3":"Laekna Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Laekna Therapeutics \/ Innovent Biologics","highestDevelopmentStatusID":"5","companyTruncated":"Laekna Therapeutics \/ Innovent Biologics"},{"orgOrder":0,"company":"Ionetix","sponsor":"Precision Molecular","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"January 2022","year":"2022","type":"Agreement","leadProduct":"PMI21","moa":"PSMA","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ionetix","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Ionetix \/ Precision Molecular","highestDevelopmentStatusID":"5","companyTruncated":"Ionetix \/ Precision Molecular"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Cancer Research","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"January 2022","year":"2022","type":"Licensing Agreement","leadProduct":"IDE161","moa":"PARG","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Ideaya Biosciences \/ Cancer Research Technology Ltd.","highestDevelopmentStatusID":"5","companyTruncated":"Ideaya Biosciences \/ Cancer Research Technology Ltd."},{"orgOrder":0,"company":"Hillstream BioPharma","sponsor":"ThinkEquity","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"January 2022","year":"2022","type":"Public Offering","leadProduct":"HSB-1216","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hillstream BioPharma","amount2":0.02,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"","sponsorNew":"Hillstream BioPharma \/ ThinkEquity","highestDevelopmentStatusID":"5","companyTruncated":"Hillstream BioPharma \/ ThinkEquity"},{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"University College London","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"QN-302","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Qualigen Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Qualigen Therapeutics \/ University College London","highestDevelopmentStatusID":"5","companyTruncated":"Qualigen Therapeutics \/ University College London"},{"orgOrder":0,"company":"Amunix","sponsor":"Sanofi","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"February 2022","year":"2022","type":"Acquisition","leadProduct":"AMX-818","moa":"Dysregulated protease","graph1":"Oncology","graph2":"IND Enabling","graph3":"Amunix","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Amunix \/ Sanofi","highestDevelopmentStatusID":"5","companyTruncated":"Amunix \/ Sanofi"},{"orgOrder":0,"company":"PharmaCyte Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Encapsulated Live Cells Converting Ifosamide","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"PharmaCyte Biotech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"PharmaCyte Biotech \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"PharmaCyte Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"QN-302","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Qualigen Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Qualigen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Qualigen Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Hillstream BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"HSB-1216","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hillstream BioPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Hillstream BioPharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Hillstream BioPharma \/ Not Applicable"},{"orgOrder":0,"company":"Privo Technologies","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"February 2022","year":"2022","type":"Funding","leadProduct":"Cisplatin","moa":"DNA","graph1":"Oncology","graph2":"IND Enabling","graph3":"Privo Technologies","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Privo Technologies \/ National Cancer Institute","highestDevelopmentStatusID":"5","companyTruncated":"Privo Technologies \/ National Cancer Institute"},{"orgOrder":0,"company":"Targovax","sponsor":"Agenus","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Vaccine","date":"March 2022","year":"2022","type":"Collaboration","leadProduct":"QS-21 Stimulon","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Targovax","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Targovax \/ Agenus","highestDevelopmentStatusID":"5","companyTruncated":"Targovax \/ Agenus"},{"orgOrder":0,"company":"Genome & Company","sponsor":"MSD Pharmaceuticals","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"March 2022","year":"2022","type":"Collaboration","leadProduct":"GEN-001","moa":"IL-7","graph1":"Oncology","graph2":"IND Enabling","graph3":"Genome & Company","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Genome & Company \/ MSD","highestDevelopmentStatusID":"5","companyTruncated":"Genome & Company \/ MSD"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Imiquimod","moa":"CTLA-4","graph1":"Oncology","graph2":"IND Enabling","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Solution","sponsorNew":"UroGen Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"UroGen Pharma \/ Not Applicable"},{"orgOrder":0,"company":"A2 Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Tmod CEA CAR T Cell Therapy","moa":"Carcinoembryonic antigen","graph1":"Oncology","graph2":"IND Enabling","graph3":"A2 Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"A2 Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"A2 Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"RedCloud Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"H002","moa":"EGFR","graph1":"Oncology","graph2":"IND Enabling","graph3":"RedCloud Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"RedCloud Bio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"RedCloud Bio \/ Not Applicable"},{"orgOrder":0,"company":"Hillstream BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"HSB-1216","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hillstream BioPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Hillstream BioPharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Hillstream BioPharma \/ Not Applicable"},{"orgOrder":0,"company":"Kinnate Biopharma","sponsor":"Tempus","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"KIN004","moa":"CDK12","graph1":"Oncology","graph2":"IND Enabling","graph3":"Kinnate Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Kinnate Biopharma \/ Tempus","highestDevelopmentStatusID":"5","companyTruncated":"Kinnate Biopharma \/ Tempus"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"BAL0891","moa":"Threonine tyrosine kinase","graph1":"Oncology","graph2":"IND Enabling","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Basilea Pharmaceutica \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Basilea Pharmaceutica \/ Not Applicable"},{"orgOrder":0,"company":"Orum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"ORM-5029","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Orum Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Orum Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Orum Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"CFT8634","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"C4 Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"C4 Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"C4 Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Adagene Suzhou Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"ADG138","moa":"HER2","graph1":"Oncology","graph2":"IND Enabling","graph3":"Adagene Suzhou Limited","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Adagene Suzhou Limited \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Adagene Suzhou Limited \/ Not Applicable"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"ATYR2810","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"aTyr Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"aTyr Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Palleon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Bi-Sialidase","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Palleon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Palleon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Palleon Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Asher Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"AB248","moa":"IL-2","graph1":"Oncology","graph2":"IND Enabling","graph3":"Asher Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Asher Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Asher Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Kairos Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"KROS-201","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Kairos Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Kairos Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Kairos Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Affini-T Therapeutics","sponsor":"Vida Ventures","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"March 2022","year":"2022","type":"Financing","leadProduct":"TCR T-cell Therapy","moa":"KRAS G12V","graph1":"Oncology","graph2":"IND Enabling","graph3":"Affini-T Therapeutics","amount2":0.17999999999999999,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.17999999999999999,"dosageForm":"","sponsorNew":"Affini-T Therapeutics \/ Vida Ventures","highestDevelopmentStatusID":"5","companyTruncated":"Affini-T Therapeutics \/ Vida Ventures"},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Cellectis","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"IOV-4001","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Iovance Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Iovance Biotherapeutics \/ Cellectis","highestDevelopmentStatusID":"5","companyTruncated":"Iovance Biotherapeutics \/ Cellectis"},{"orgOrder":0,"company":"Duet BioTherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"CpG-STAT3siRNA","moa":"STAT3 protein","graph1":"Oncology","graph2":"IND Enabling","graph3":"Duet BioTherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Duet BioTherapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Duet BioTherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"QN-302","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Qualigen Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Qualigen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Qualigen Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"CytoImmune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"CYTO NK-201","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"CytoImmune Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"CytoImmune Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"CytoImmune Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Virtuoso Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Bispecific Antibody","moa":"CD38\/ICAM-1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Virtuoso Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Virtuoso Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Virtuoso Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Zalifrelimab","moa":"TLR7","graph1":"Oncology","graph2":"IND Enabling","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"UroGen Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"UroGen Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Gadeta","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"GDT002","moa":"Gamma Delta T cell","graph1":"Oncology","graph2":"IND Enabling","graph3":"Gadeta","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Gadeta \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Gadeta \/ Not Applicable"},{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"QN-302","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Qualigen Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Qualigen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Qualigen Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Compass Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"CTX-8371","moa":"PD-L1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Compass Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Compass Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Compass Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Gnubiotics Sciences","sponsor":"University of Zurich","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Peptide","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"GCX","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Gnubiotics Sciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Gnubiotics Sciences \/ University of Zurich","highestDevelopmentStatusID":"5","companyTruncated":"Gnubiotics Sciences \/ University of Zurich"},{"orgOrder":0,"company":"Atreca","sponsor":"Zymeworks","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"April 2022","year":"2022","type":"Licensing Agreement","leadProduct":"ATRC-301","moa":"Ephrin type A receptor 2","graph1":"Oncology","graph2":"IND Enabling","graph3":"Atreca","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Atreca \/ Zymeworks","highestDevelopmentStatusID":"5","companyTruncated":"Atreca \/ Zymeworks"},{"orgOrder":0,"company":"Bright Peak Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"BPT-143","moa":"IL-2","graph1":"Oncology","graph2":"IND Enabling","graph3":"Bright Peak Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Bright Peak Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Bright Peak Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"JS006","moa":"CD112R","graph1":"Oncology","graph2":"IND Enabling","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Shanghai Junshi Biosciences \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Shanghai Junshi Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"ASC60","moa":"Fatty acid synthase","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ascletis Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Ascletis Pharma \/ Not Applicable"},{"orgOrder":0,"company":"iOmx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"OMX-0407","moa":"SIK3","graph1":"Oncology","graph2":"IND Enabling","graph3":"iOmx Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"iOmx Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"iOmx Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"RedCloud Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"H002","moa":"EGFR","graph1":"Oncology","graph2":"IND Enabling","graph3":"RedCloud Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"RedCloud Bio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"RedCloud Bio \/ Not Applicable"},{"orgOrder":0,"company":"OncoMyx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"OM1","moa":"IL-15","graph1":"Oncology","graph2":"IND Enabling","graph3":"OncoMyx Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"OncoMyx Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"OncoMyx Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Asher Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"AB248","moa":"IL-2","graph1":"Oncology","graph2":"IND Enabling","graph3":"Asher Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Asher Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Asher Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Elpis Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"EPIM-001","moa":"IL-2 beta receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Elpis Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Elpis Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Elpis Biopharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Orum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"ORM-5029","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Orum Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Orum Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Orum Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Bantam Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"BTM-3566","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Bantam Pharmaceutical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bantam Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Bantam Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Cellectis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"UCART20x22","moa":"CD20\/CD22","graph1":"Oncology","graph2":"IND Enabling","graph3":"Cellectis","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Cellectis \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Cellectis \/ Not Applicable"},{"orgOrder":0,"company":"Adagene Suzhou Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"ADG138","moa":"HER2\/CD3","graph1":"Oncology","graph2":"IND Enabling","graph3":"Adagene Suzhou Limited","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Adagene Suzhou Limited \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Adagene Suzhou Limited \/ Not Applicable"},{"orgOrder":0,"company":"Compass Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"CTX-8371","moa":"PD-L1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Compass Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Compass Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Compass Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Umoja Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"UB-TT170","moa":"Folate receptor alpha","graph1":"Oncology","graph2":"IND Enabling","graph3":"Umoja Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Umoja Biopharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Umoja Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"EDIT-202","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Editas Medicine \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Editas Medicine \/ Not Applicable"},{"orgOrder":0,"company":"T-knife","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"TK-2504","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"T-knife","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"T-knife \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"T-knife \/ Not Applicable"},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"GD-2 SADA","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Y-mAbs Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Y-mAbs Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Y-mAbs Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Insilico Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"ISM025","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Insilico Medicine","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Insilico Medicine \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Insilico Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"QN-302","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Qualigen Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Qualigen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Qualigen Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"ATYR2810","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"aTyr Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"aTyr Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Akeso","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"AK131","moa":"Adenosine receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Akeso \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Akeso \/ Not Applicable"},{"orgOrder":0,"company":"Immune-Onc Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"IO-106","moa":"LAIR-1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Immune-Onc Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Immune-Onc Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Immune-Onc Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Dragon Boat Pharmaceutical","sponsor":"Sanyou Biopharmaceuticals","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"BC008","moa":"CLDN18.2","graph1":"Oncology","graph2":"IND Enabling","graph3":"Dragon Boat Pharmaceutical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Dragon Boat Pharmaceutical \/ Sanyou Biopharmaceuticals","highestDevelopmentStatusID":"5","companyTruncated":"Dragon Boat Pharmaceutical \/ Sanyou Biopharmaceuticals"},{"orgOrder":0,"company":"JW Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Relmacabtagene Autoleucel","moa":"CD19","graph1":"Oncology","graph2":"IND Enabling","graph3":"JW Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"JW Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"JW Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Biovaxys","sponsor":"Deaconess Research Institute","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Vaccine","date":"April 2022","year":"2022","type":"Agreement","leadProduct":"BVX-0918","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Biovaxys","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biovaxys \/ Deaconess Research Institute","highestDevelopmentStatusID":"5","companyTruncated":"Biovaxys \/ Deaconess Research Institute"},{"orgOrder":0,"company":"TScan Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"TSC-200-A02","moa":"MHC","graph1":"Oncology","graph2":"IND Enabling","graph3":"TScan Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"TScan Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"TScan Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Umoja Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"CAR T-cell Therapy","moa":"Folate receptor alpha","graph1":"Oncology","graph2":"IND Enabling","graph3":"Umoja Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Umoja Biopharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Umoja Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Curia","sponsor":"BryoLogyx Inc","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"Bryostatin-1","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Curia","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Curia \/ BryoLogyx","highestDevelopmentStatusID":"5","companyTruncated":"Curia \/ BryoLogyx"},{"orgOrder":0,"company":"Elpiscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"ES014","moa":"CD39","graph1":"Oncology","graph2":"IND Enabling","graph3":"Elpiscience","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Elpiscience \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Elpiscience \/ Not Applicable"},{"orgOrder":0,"company":"Neogene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"NT-125","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Neogene","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Neogene \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Neogene \/ Not Applicable"},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"ALEXIS-PRO-1","moa":"PD-L1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Kiromic BioPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Kiromic BioPharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Kiromic BioPharma \/ Not Applicable"},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"CRB-601","moa":"AlphaVbeta8 integrin","graph1":"Oncology","graph2":"IND Enabling","graph3":"Corbus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Corbus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Corbus Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Affimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"AFM28","moa":"CD123\/CD16A","graph1":"Oncology","graph2":"IND Enabling","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Affimed \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Affimed \/ Not Applicable"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"SP-3164","moa":"Cereblon","graph1":"Oncology","graph2":"IND Enabling","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Salarius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Salarius Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Acuitas","sponsor":"Myeloid Therapeutics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"May 2022","year":"2022","type":"Agreement","leadProduct":"MT-301","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Acuitas","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Acuitas \/ Myeloid Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Acuitas \/ Myeloid Therapeutics"},{"orgOrder":0,"company":"GeneQuantum Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"GQ1005","moa":"HER2 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"GeneQuantum Healthcare","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"GeneQuantum Healthcare \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"GeneQuantum Healthcare \/ Not Applicable"},{"orgOrder":0,"company":"RootPath","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"InfiniTIL","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"RootPath","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"RootPath \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"RootPath \/ Not Applicable"},{"orgOrder":0,"company":"GigaGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"GIGA-564","moa":"CTLA-4","graph1":"Oncology","graph2":"IND Enabling","graph3":"GigaGen","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"GigaGen \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"GigaGen \/ Not Applicable"},{"orgOrder":0,"company":"TScan Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"TSC-200-A02","moa":"MHC","graph1":"Oncology","graph2":"IND Enabling","graph3":"TScan Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"TScan Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"TScan Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"177Lu-PNT2004","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Point Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Point Biopharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Point Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Full-Life Technologies","sponsor":"Sequoia","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","date":"May 2022","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Full-Life Technologies","amount2":0.040000000000000001,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Full-Life Technologies \/ Sequoia","highestDevelopmentStatusID":"5","companyTruncated":"Full-Life Technologies \/ Sequoia"},{"orgOrder":0,"company":"Zumutor Biologics","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"February 2020","year":"2020","type":"Collaboration","leadProduct":"ZM008","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Zumutor Biologics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Zumutor Biologics \/ Catalent","highestDevelopmentStatusID":"5","companyTruncated":"Zumutor Biologics \/ Catalent"},{"orgOrder":0,"company":"Immunome","sponsor":"Fox Chase Cancer Center","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"IMM-ONC-01","moa":"IL-38","graph1":"Oncology","graph2":"IND Enabling","graph3":"Immunome","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Immunome \/ Fox Chase Cancer Center","highestDevelopmentStatusID":"5","companyTruncated":"Immunome \/ Fox Chase Cancer Center"},{"orgOrder":0,"company":"Calidi Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"AD-MSC Based Oncolytic Virus","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Calidi Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Calidi Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Calidi Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Oncomatryx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"OMTX705","moa":"Alpha Fibroblast activation","graph1":"Oncology","graph2":"IND Enabling","graph3":"Oncomatryx","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Oncomatryx \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Oncomatryx \/ Not Applicable"},{"orgOrder":0,"company":"Yumanity Therapeutics","sponsor":"Kineta","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"June 2022","year":"2022","type":"Merger","leadProduct":"KVA12.1","moa":"VISTA","graph1":"Oncology","graph2":"IND Enabling","graph3":"Yumanity Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Yumanity Therapeutics \/ Kineta","highestDevelopmentStatusID":"5","companyTruncated":"Yumanity Therapeutics \/ Kineta"},{"orgOrder":0,"company":"Asher Biotherapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"June 2022","year":"2022","type":"Collaboration","leadProduct":"AB248","moa":"IL2 Signalling Pathway","graph1":"Oncology","graph2":"IND Enabling","graph3":"Asher Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Asher Biotherapeutics \/ Merck","highestDevelopmentStatusID":"5","companyTruncated":"Asher Biotherapeutics \/ Merck"},{"orgOrder":0,"company":"EpimAb Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"FIT-013a","moa":"EGFR","graph1":"Oncology","graph2":"IND Enabling","graph3":"EpimAb Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"EpimAb Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"EpimAb Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"QN-302","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Qualigen Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Qualigen Therapeutics \/ Merck","highestDevelopmentStatusID":"5","companyTruncated":"Qualigen Therapeutics \/ Merck"},{"orgOrder":0,"company":"Alpha Tau Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Radium-224","moa":"Alpha radiation","graph1":"Oncology","graph2":"IND Enabling","graph3":"Alpha Tau Medical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Alpha Tau Medical \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Alpha Tau Medical \/ Not Applicable"},{"orgOrder":0,"company":"Affimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"AFM28","moa":"CD123\/CD16A","graph1":"Oncology","graph2":"IND Enabling","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Affimed \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Affimed \/ Not Applicable"},{"orgOrder":0,"company":"Jubilant Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"JBI-2174","moa":"PD-L1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Jubilant Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Jubilant Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Jubilant Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"LB101","moa":"PD-L1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Centessa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Centessa Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Centessa Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Metagenomi","sponsor":"Affini-T Therapeutics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"June 2022","year":"2022","type":"Partnership","leadProduct":"AFNT-111","moa":"KRAS G12V","graph1":"Oncology","graph2":"IND Enabling","graph3":"Metagenomi","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Metagenomi \/ Affini-T Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Metagenomi \/ Affini-T Therapeutics"},{"orgOrder":0,"company":"Invectys","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"June 2022","year":"2022","type":"Collaboration","leadProduct":"HLA-G\/CAR-T Cell Therapy","moa":"HLA-G","graph1":"Oncology","graph2":"IND Enabling","graph3":"Invectys","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Invectys \/ MD Anderson","highestDevelopmentStatusID":"5","companyTruncated":"Invectys \/ MD Anderson"},{"orgOrder":0,"company":"Bio Elpida","sponsor":"Biovaxys","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Vaccine","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"BVX-0918","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Bio Elpida","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Bio Elpida \/ BioVaxys Technology Corp","highestDevelopmentStatusID":"5","companyTruncated":"Bio Elpida \/ BioVaxys Technology Corp"},{"orgOrder":0,"company":"Nammi Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"QXL138AM","moa":"CD138","graph1":"Oncology","graph2":"IND Enabling","graph3":"Nammi Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Nammi Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Nammi Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Cellenkos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"CK0804","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Cellenkos","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Cellenkos \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Cellenkos \/ Not Applicable"},{"orgOrder":0,"company":"Biovaxys","sponsor":"Hospices Civils de Lyon","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Vaccine","date":"May 2022","year":"2022","type":"Agreement","leadProduct":"BVX-0918","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Biovaxys","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Biovaxys \/ Hospices Civils de Lyon","highestDevelopmentStatusID":"5","companyTruncated":"Biovaxys \/ Hospices Civils de Lyon"},{"orgOrder":0,"company":"Hillstream BioPharma","sponsor":"Sapien Biosciences","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"June 2022","year":"2022","type":"Collaboration","leadProduct":"HSB-1216","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hillstream BioPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Hillstream BioPharma \/ Sapien Biosciences","highestDevelopmentStatusID":"5","companyTruncated":"Hillstream BioPharma \/ Sapien Biosciences"},{"orgOrder":0,"company":"Bantam Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"BTM-3566","moa":"HRI Kinase","graph1":"Oncology","graph2":"IND Enabling","graph3":"Bantam Pharmaceutical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Bantam Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Bantam Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"Ipsen","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"225Ac-IPN-1087","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Fusion Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Fusion Pharma \/ Ipsen","highestDevelopmentStatusID":"5","companyTruncated":"Fusion Pharma \/ Ipsen"},{"orgOrder":0,"company":"Schrodinger","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"SGR-1505","moa":"MALT1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Schrodinger","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Schrodinger \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Schrodinger \/ Not Applicable"},{"orgOrder":0,"company":"Phanes Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"PT886","moa":"Claudin18.2","graph1":"Oncology","graph2":"IND Enabling","graph3":"Phanes Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Phanes Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Phanes Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"Hande Sciences","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"July 2022","year":"2022","type":"Partnership","leadProduct":"QN-302","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Qualigen Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Qualigen Therapeutics \/ Hande Sciences","highestDevelopmentStatusID":"5","companyTruncated":"Qualigen Therapeutics \/ Hande Sciences"},{"orgOrder":0,"company":"Alpha Tau Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Radium-224","moa":"Alpha radiation","graph1":"Oncology","graph2":"IND Enabling","graph3":"Alpha Tau Medical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Alpha Tau Medical \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Alpha Tau Medical \/ Not Applicable"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"ICP-490","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"InnoCare Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"InnoCare Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Sunho Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"IAP0971","moa":"PD-1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Sunho Pharmaceutical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sunho Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Sunho Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"NexImmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"NEXI-003","moa":"CD3\/CD4","graph1":"Oncology","graph2":"IND Enabling","graph3":"NexImmune","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"NexImmune \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"NexImmune \/ Not Applicable"},{"orgOrder":0,"company":"Escend Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"ES-3000","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Escend Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Escend Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Escend Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"STP705","moa":"TGF beta-1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sirnaomics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Sirnaomics \/ Not Applicable"},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Vaccine","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"HB-300","moa":"PAP\/PSA","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hookipa Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Hookipa Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Hookipa Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Cellectis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"UCART20x22","moa":"CD20\/CD22","graph1":"Oncology","graph2":"IND Enabling","graph3":"Cellectis","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Cellectis \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Cellectis \/ Not Applicable"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"6-Thio-2-Deoxyguanosine","moa":"Telomere","graph1":"Oncology","graph2":"IND Enabling","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"MAIA Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"MAIA Biotechnology \/ Not Applicable"},{"orgOrder":0,"company":"Jubilant Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"JBI-778","moa":"PRMT5","graph1":"Oncology","graph2":"IND Enabling","graph3":"Jubilant Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Jubilant Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Jubilant Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Cullgen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"CG001419","moa":"TRK protein","graph1":"Oncology","graph2":"IND Enabling","graph3":"Cullgen","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Cullgen \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Cullgen \/ Not Applicable"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Quantum Leap Healthcare","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"CD47","graph1":"Oncology","graph2":"IND Enabling","graph3":"ALX Oncology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ALX Oncology \/ Quantum Leap Healthcare","highestDevelopmentStatusID":"5","companyTruncated":"ALX Oncology \/ Quantum Leap Healthcare"},{"orgOrder":0,"company":"Carina Biotech","sponsor":"Tenmile","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"August 2022","year":"2022","type":"Financing","leadProduct":"LGR5 CAR-T Cell Therapy","moa":"LGR5","graph1":"Oncology","graph2":"IND Enabling","graph3":"Carina Biotech","amount2":0.01,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"","sponsorNew":"Carina Biotech \/ Tenmile","highestDevelopmentStatusID":"5","companyTruncated":"Carina Biotech \/ Tenmile"},{"orgOrder":0,"company":"Ocean Biomedical","sponsor":"Aesther","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"August 2022","year":"2022","type":"Agreement","leadProduct":"OCX-253","moa":"CHI3L1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ocean Biomedical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Ocean Biomedical \/ Aesther","highestDevelopmentStatusID":"5","companyTruncated":"Ocean Biomedical \/ Aesther"},{"orgOrder":0,"company":"GT Biopharma","sponsor":"Cytovance Biologics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"August 2022","year":"2022","type":"Agreement","leadProduct":"GTB-3650","moa":"IL-15","graph1":"Oncology","graph2":"IND Enabling","graph3":"GT Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"GT Biopharma \/ Cytovance Biologics","highestDevelopmentStatusID":"5","companyTruncated":"GT Biopharma \/ Cytovance Biologics"},{"orgOrder":0,"company":"Selecxine","sponsor":"GenScript ProBio","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"SLC-3010","moa":"IL-2","graph1":"Oncology","graph2":"IND Enabling","graph3":"Selecxine","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Selecxine \/ GenScript ProBio","highestDevelopmentStatusID":"5","companyTruncated":"Selecxine \/ GenScript ProBio"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Connoya Biomedical Technology","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"CM369","moa":"CCR8","graph1":"Oncology","graph2":"IND Enabling","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"InnoCare Pharma \/ Keymed Biosciences","highestDevelopmentStatusID":"5","companyTruncated":"InnoCare Pharma \/ Keymed Biosciences"},{"orgOrder":0,"company":"Tachyon Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"TACH101","moa":"KDM4 histone demethylase","graph1":"Oncology","graph2":"IND Enabling","graph3":"Tachyon Technologies","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Tachyon Technologies \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Tachyon Technologies \/ Not Applicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"JS110","moa":"XPO1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shanghai Junshi Biosciences \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Shanghai Junshi Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"ONK Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"ONKT102","moa":"CD38","graph1":"Oncology","graph2":"IND Enabling","graph3":"ONK Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"ONK Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"ONK Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Actinium-225-Vofatamab","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Fusion Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Fusion Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Fusion Pharma \/ Not Applicable"},{"orgOrder":0,"company":"ArsenalBio","sponsor":"Softbank Vision Fund 2","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"September 2022","year":"2022","type":"Series B Financing","leadProduct":"AB-1015","moa":"CTLA-4x\/OX40","graph1":"Oncology","graph2":"IND Enabling","graph3":"ArsenalBio","amount2":0.22,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.22,"dosageForm":"","sponsorNew":"ArsenalBio \/ Softbank Vision Fund 2","highestDevelopmentStatusID":"5","companyTruncated":"ArsenalBio \/ Softbank Vision Fund 2"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"IMM-1-104","moa":"MEK","graph1":"Oncology","graph2":"IND Enabling","graph3":"Immuneering Corporation","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Immuneering Corporation \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Immuneering Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"IMX-110","moa":"Polykinase","graph1":"Oncology","graph2":"IND Enabling","graph3":"Immix Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Immix Biopharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Immix Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Ocean Biomedical","sponsor":"Aesther Healthcare Acquisition Corp","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2022","year":"2022","type":"Agreement","leadProduct":"OCX-253","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ocean Biomedical","amount2":0.080000000000000002,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Ocean Biomedical \/ Aesther Healthcare Acquisition Corp","highestDevelopmentStatusID":"5","companyTruncated":"Ocean Biomedical \/ Aesther Healthcare Acquisition Corp"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"ICP-248","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"InnoCare Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"InnoCare Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"LB101","moa":"PD-L1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Centessa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Centessa Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Centessa Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"LP-184","moa":"DNA synthesis","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Lantern Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Lantern Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"QN-302","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Qualigen Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Qualigen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Qualigen Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Roca Therapeutics","sponsor":"3B Future Health Fund II","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"September 2022","year":"2022","type":"Financing","leadProduct":"RCT001","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Roca Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Roca Therapeutics \/ 3B Future Health Fund II","highestDevelopmentStatusID":"5","companyTruncated":"Roca Therapeutics \/ 3B Future Health Fund II"},{"orgOrder":0,"company":"Artiva Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"CAR-NK Cell Therapy","moa":"CD16","graph1":"Oncology","graph2":"IND Enabling","graph3":"Artiva Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Artiva Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Artiva Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Pheon Therapeutics","sponsor":"Brandon Capital","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2022","year":"2022","type":"Series A Financing","leadProduct":"PHN-010","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Pheon Therapeutics","amount2":0.070000000000000007,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"Pheon Therapeutics \/ Brandon Capital","highestDevelopmentStatusID":"5","companyTruncated":"Pheon Therapeutics \/ Brandon Capital"},{"orgOrder":0,"company":"Oxford Biotherapeutics","sponsor":"Genmab","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"October 2022","year":"2022","type":"Licensing Agreement","leadProduct":"OBT700","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Oxford Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Oxford Biotherapeutics \/ Genmab","highestDevelopmentStatusID":"5","companyTruncated":"Oxford Biotherapeutics \/ Genmab"},{"orgOrder":0,"company":"Ocean Biomedical","sponsor":"Aesther Healthcare","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"October 2022","year":"2022","type":"Merger","leadProduct":"OCX-253","moa":"CHI3L1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ocean Biomedical","amount2":0.080000000000000002,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Ocean Biomedical \/ Aesther Healthcare","highestDevelopmentStatusID":"5","companyTruncated":"Ocean Biomedical \/ Aesther Healthcare"},{"orgOrder":0,"company":"Seneca Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"SVV-001","moa":"TEM8","graph1":"Oncology","graph2":"IND Enabling","graph3":"Seneca Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Seneca Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Seneca Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Theseus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"THE-349","moa":"EGFR","graph1":"Oncology","graph2":"IND Enabling","graph3":"Theseus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Theseus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Theseus Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"ONCT-808","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Oncternal Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Oncternal Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Oncternal Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"MiNK Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"MiNK-413","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"MiNK Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"MiNK Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"MiNK Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Tango Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"TNG260","moa":"CoREST-HDAC","graph1":"Oncology","graph2":"IND Enabling","graph3":"Tango Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Tango Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Tango Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Oncorus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"ONCR-788","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Oncorus","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Oncorus \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Oncorus \/ Not Applicable"},{"orgOrder":0,"company":"Calidi Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"AD-MSC Based Oncolytic Virus","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Calidi Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Calidi Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Calidi Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Omega Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"OTX-2101","moa":"c-Myc cell proliferation","graph1":"Oncology","graph2":"IND Enabling","graph3":"Omega Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Omega Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Omega Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Galectin Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Belapectin","moa":"Galectin-3","graph1":"Oncology","graph2":"IND Enabling","graph3":"Galectin Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Galectin Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Galectin Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"CRB-601","moa":"AlphaVbeta8 integrin","graph1":"Oncology","graph2":"IND Enabling","graph3":"Corbus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Corbus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Corbus Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Prelude Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"PRT3789","moa":"SMARCA2 protein","graph1":"Oncology","graph2":"IND Enabling","graph3":"Prelude Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Prelude Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Prelude Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"EvolveImmune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"EV104","moa":"CD3","graph1":"Oncology","graph2":"IND Enabling","graph3":"EvolveImmune Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"EvolveImmune Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"EvolveImmune Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"SP-3164","moa":"Cereblon","graph1":"Oncology","graph2":"IND Enabling","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Salarius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Salarius Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"INKmune","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"INmune Bio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"INmune Bio \/ Not Applicable"},{"orgOrder":0,"company":"EvolveImmune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"EV104","moa":"CD3","graph1":"Oncology","graph2":"IND Enabling","graph3":"EvolveImmune Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"EvolveImmune Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"EvolveImmune Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"LP-184","moa":"DNA synthesis","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Lantern Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Lantern Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Theseus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"THE-349","moa":"EGFR","graph1":"Oncology","graph2":"IND Enabling","graph3":"Theseus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Theseus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Theseus Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Sairopa","sponsor":"Exelixis","pharmaFlowCategory":"D","upfrontCash":"$40.0 million","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"November 2022","year":"2022","type":"Collaboration","leadProduct":"ADU-1805","moa":"SIRP alpha","graph1":"Oncology","graph2":"IND Enabling","graph3":"Sairopa","amount2":0.34000000000000002,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.34000000000000002,"dosageForm":"","sponsorNew":"Sairopa \/ Exelixis","highestDevelopmentStatusID":"5","companyTruncated":"Sairopa \/ Exelixis"},{"orgOrder":0,"company":"Res Nova Bio","sponsor":"Therapeutic Solutions","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","date":"October 2022","year":"2022","type":"Demerger","leadProduct":"ValloVax","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Res Nova Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Res Nova Bio \/ Therapeutic Solutions International","highestDevelopmentStatusID":"5","companyTruncated":"Res Nova Bio \/ Therapeutic Solutions International"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Avadomide","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Salarius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Salarius Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"SIM0237","moa":"PD-L1\/IL-15","graph1":"Oncology","graph2":"IND Enabling","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Flare Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"FX-909","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Flare Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Flare Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Flare Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Turnstone Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"TIDAL-01","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Turnstone Biologics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Turnstone Biologics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Turnstone Biologics \/ Not Applicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"ATG-017","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Antengene \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Antengene \/ Not Applicable"},{"orgOrder":0,"company":"Transgene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Vaccine","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Avelumab","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Transgene \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Transgene \/ Not Applicable"},{"orgOrder":0,"company":"Senti Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"SENTI-202","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Senti Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Senti Biosciences \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Senti Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Affimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"AFM28","moa":"CD123\/CD16A","graph1":"Oncology","graph2":"IND Enabling","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Affimed \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Affimed \/ Not Applicable"},{"orgOrder":0,"company":"GT Biopharma","sponsor":"Fate Therapeutics","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"CAR NK Cell Therapy","moa":"CD33","graph1":"Oncology","graph2":"IND Enabling","graph3":"GT Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"GT Biopharma \/ Fate Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"GT Biopharma \/ Fate Therapeutics"},{"orgOrder":0,"company":"Schrodinger","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"SGR-2921","moa":"CDC7","graph1":"Oncology","graph2":"IND Enabling","graph3":"Schrodinger","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Schrodinger \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Schrodinger \/ Not Applicable"},{"orgOrder":0,"company":"Asher Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"AB821","moa":"IL-21","graph1":"Oncology","graph2":"IND Enabling","graph3":"Asher Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Asher Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Asher Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Molecular Templates","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"MT-8421","moa":"CTLA-4","graph1":"Oncology","graph2":"IND Enabling","graph3":"Molecular Templates","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Molecular Templates \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Molecular Templates \/ Not Applicable"},{"orgOrder":0,"company":"Oxilio","sponsor":"Quotient Sciences","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"OXL001","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Oxilio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Oxilio \/ Quotient Sciences","highestDevelopmentStatusID":"5","companyTruncated":"Oxilio \/ Quotient Sciences"},{"orgOrder":0,"company":"Res Nova Bio","sponsor":"Veltmeyer MD","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","date":"November 2022","year":"2022","type":"Collaboration","leadProduct":"ValloVax","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Res Nova Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Res Nova Bio \/ Veltmeyer MD","highestDevelopmentStatusID":"5","companyTruncated":"Res Nova Bio \/ Veltmeyer MD"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Navrogen","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"November 2022","year":"2022","type":"Agreement","leadProduct":"NAV-001","moa":"Mesothelin","graph1":"Oncology","graph2":"IND Enabling","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"National Cancer Institute \/ Navrogen","highestDevelopmentStatusID":"5","companyTruncated":"National Cancer Institute \/ Navrogen"},{"orgOrder":0,"company":"Affini-T Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"AFNT-111","moa":"KRAS G12V","graph1":"Oncology","graph2":"IND Enabling","graph3":"Affini-T Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Affini-T Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Affini-T Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"HLX22","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Alligator Bioscience","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Alligator Bioscience \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Alligator Bioscience \/ Not Applicable"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Iadademstat","moa":"LSD1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Oryzon Genomics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Oryzon Genomics \/ Not Applicable"},{"orgOrder":0,"company":"TScan Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"TSC-203","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"TScan Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"TScan Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"TScan Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"HiFiBiO Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"November 2022","year":"2022","type":"Agreement","leadProduct":"HFB200603","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"HiFiBiO Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"HiFiBiO Therapeutics \/ Novartis","highestDevelopmentStatusID":"5","companyTruncated":"HiFiBiO Therapeutics \/ Novartis"},{"orgOrder":0,"company":"Scorpion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"STX-478","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Scorpion Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Scorpion Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Scorpion Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"SAR-bombesin","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Clarity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Clarity Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Clarity Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"LP-184","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Lantern Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Lantern Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Marker Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"MT-601","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Marker Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Marker Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Marker Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"WP1122","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Moleculin Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"QN-302","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Qualigen Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Qualigen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Qualigen Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Scorpion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"STX-478","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Scorpion Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Scorpion Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Scorpion Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Molecular Targeting Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Peptide","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"177Lu-DOTA-EB-TATE","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Molecular Targeting Technologies","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Molecular Targeting Technologies \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Molecular Targeting Technologies \/ Not Applicable"},{"orgOrder":0,"company":"Schrodinger","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"SGR-2921","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Schrodinger","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Schrodinger \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Schrodinger \/ Not Applicable"},{"orgOrder":0,"company":"Erasca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"ERAS-3490","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Erasca","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Erasca \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Erasca \/ Not Applicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"LP-284","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Lantern Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Lantern Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Invectys","sponsor":"CTMA","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"HLA-G\/CAR-T Cell Therapy","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Invectys","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Invectys \/ CTMA","highestDevelopmentStatusID":"5","companyTruncated":"Invectys \/ CTMA"},{"orgOrder":0,"company":"Invectys","sponsor":"CTMC","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"HLA-G\/CAR-T Cell Therapy","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Invectys","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Invectys \/ CTMC","highestDevelopmentStatusID":"5","companyTruncated":"Invectys \/ CTMC"},{"orgOrder":0,"company":"Phio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"PH-762","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Phio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Phio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Phio Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Affimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"AFM28","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Affimed \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Affimed \/ Not Applicable"},{"orgOrder":0,"company":"SURGE Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Resiquimod","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"SURGE Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"SURGE Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"SURGE Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"LP-284","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Lantern Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Lantern Pharma \/ Not Applicable"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"BIOKEY","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"BLEX 404","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"ABVC BioPharma \/ BioKey","highestDevelopmentStatusID":"5","companyTruncated":"ABVC BioPharma \/ BioKey"},{"orgOrder":0,"company":"Frontier Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"FMC-376","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Frontier Medicine","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Frontier Medicine \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Frontier Medicine \/ Not Applicable"},{"orgOrder":0,"company":"CASI Pharmaceuticals","sponsor":"Cleave Therapeutics","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"CB-5339","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"CASI Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CASI Pharmaceuticals \/ Cleave Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"CASI Pharmaceuticals \/ Cleave Therapeutics"},{"orgOrder":0,"company":"Integral Molecular","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"CTIM-76","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Integral Molecular","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Integral Molecular \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Integral Molecular \/ Not Applicable"},{"orgOrder":0,"company":"HiFiBiO Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"HFB200603","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"HiFiBiO Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"HiFiBiO Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"HiFiBiO Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"QN-302","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Qualigen Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Qualigen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Qualigen Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Shoreline Biosciences","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"January 2023","year":"2023","type":"Acquisition","leadProduct":"EDIT-202","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Editas Medicine \/ Shoreline Biosciences","highestDevelopmentStatusID":"5","companyTruncated":"Editas Medicine \/ Shoreline Biosciences"},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","upfrontCash":"$15.0 million","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"January 2023","year":"2023","type":"Partnership","leadProduct":"RP-2119","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Repare Therapeutics","amount2":0.17999999999999999,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.17999999999999999,"dosageForm":"","sponsorNew":"Repare Therapeutics \/ Ono Pharmaceutical","highestDevelopmentStatusID":"5","companyTruncated":"Repare Therapeutics \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"LP-184","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Lantern Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Lantern Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"SP-3164","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Salarius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Salarius Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"MRTX1133","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Mirati Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Mirati Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Grey Wolf Therapeutics","sponsor":"Pfizer Ventures","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"January 2023","year":"2023","type":"Series B Financing","leadProduct":"Cemiplimab","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Grey Wolf Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Grey Wolf Therapeutics \/ Pfizer Ventures","highestDevelopmentStatusID":"5","companyTruncated":"Grey Wolf Therapeutics \/ Pfizer Ventures"},{"orgOrder":0,"company":"ImmunOs Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"IOS-1002","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"ImmunOs Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"ImmunOs Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"ImmunOs Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"TScan Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"TSC-204-A0201","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"TScan Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"TScan Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"TScan Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"QN-302","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Qualigen Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Qualigen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Qualigen Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"KO-2806","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Kura Oncology \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Kura Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"SC291","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Sana Biotechnology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Sana Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Sana Biotechnology \/ Not Applicable"},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"LB101","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Centessa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Centessa Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Centessa Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"SP-3164","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Salarius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Salarius Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Hillstream BioPharma","sponsor":"Dana-Farber Cancer Institute","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"January 2023","year":"2023","type":"Agreement","leadProduct":"HSB-1216","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hillstream BioPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Hillstream BioPharma \/ Dana-Farber Cancer Institute","highestDevelopmentStatusID":"5","companyTruncated":"Hillstream BioPharma \/ Dana-Farber Cancer Institute"},{"orgOrder":0,"company":"Jemincare","sponsor":"Genentech","pharmaFlowCategory":"D","upfrontCash":"$60.0 million","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","date":"August 2022","year":"2022","type":"Licensing Agreement","leadProduct":"JMKX002992","moa":"Androgen receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Jemincare","amount2":0.65000000000000002,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.65000000000000002,"dosageForm":"","sponsorNew":"Jemincare \/ Genentech","highestDevelopmentStatusID":"5","companyTruncated":"Jemincare \/ Genentech"},{"orgOrder":0,"company":"Prokarium","sponsor":"Ginkgo Bioworks","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"February 2023","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Prokarium","amount2":0.029999999999999999,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Prokarium \/ Ginkgo Bioworks","highestDevelopmentStatusID":"5","companyTruncated":"Prokarium \/ Ginkgo Bioworks"},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"PLN-101095","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Pliant Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Pliant Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Pliant Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Carina Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"CNA3103","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Carina Biotech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Carina Biotech \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Carina Biotech \/ Not Applicable"},{"orgOrder":0,"company":"NEOGAP Therapeutics","sponsor":"Karolinska University Hospital","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Personalised Tumor Trained Lymphocytes","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"NEOGAP Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"NEOGAP Therapeutics \/ Karolinska University Hospital","highestDevelopmentStatusID":"5","companyTruncated":"NEOGAP Therapeutics \/ Karolinska University Hospital"},{"orgOrder":0,"company":"Aprea Therapeutics","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"February 2023","year":"2023","type":"Funding","leadProduct":"ATRN-119","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Aprea Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Aprea Therapeutics \/ National Cancer Institute","highestDevelopmentStatusID":"5","companyTruncated":"Aprea Therapeutics \/ National Cancer Institute"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"February 2023","year":"2023","type":"Public Offering","leadProduct":"TTX-MC138","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"TransCode Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"5","companyTruncated":"TransCode Therapeutics \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Jubilant Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"JBI-778","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Jubilant Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Jubilant Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Jubilant Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"6-Thio-2\\'-Deoxyguanosine","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"MAIA Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"MAIA Biotechnology \/ Not Applicable"},{"orgOrder":0,"company":"Sairopa","sponsor":"Exelixis","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"ADU-1805","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Sairopa","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Sairopa \/ Exelixis","highestDevelopmentStatusID":"5","companyTruncated":"Sairopa \/ Exelixis"},{"orgOrder":0,"company":"BioAtla","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"BA3182","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"BioAtla","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"BioAtla \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"BioAtla \/ Not Applicable"},{"orgOrder":0,"company":"Fapon Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"FP002","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Fapon Biotech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Fapon Biotech \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Fapon Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Eucure Biopharma","sponsor":"Chipscreen NewWay Biosciences","pharmaFlowCategory":"D","upfrontCash":"$5.7 million","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"February 2023","year":"2023","type":"Licensing Agreement","leadProduct":"YH008","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Eucure Biopharma","amount2":0.089999999999999997,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Eucure Biopharma \/ Chipscreen NewWay Biosciences","highestDevelopmentStatusID":"5","companyTruncated":"Eucure Biopharma \/ Chipscreen NewWay Biosciences"},{"orgOrder":0,"company":"OriCell Therapeutics","sponsor":"RTW Investments","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"February 2023","year":"2023","type":"Series B Financing","leadProduct":"CAR-T Cell Therapy","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"OriCell Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"OriCell Therapeutics \/ RTW Investments","highestDevelopmentStatusID":"5","companyTruncated":"OriCell Therapeutics \/ RTW Investments"},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"KB-GDT-01","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Kiromic BioPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Kiromic BioPharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Kiromic BioPharma \/ Not Applicable"},{"orgOrder":0,"company":"Alpha Tau Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Radium-224","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Alpha Tau Medical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Alpha Tau Medical \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Alpha Tau Medical \/ Not Applicable"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"FloraStilbene","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Therapeutic Solutions \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Therapeutic Solutions \/ Not Applicable"},{"orgOrder":0,"company":"Estrella Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"EB103","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Estrella Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Estrella Biopharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Estrella Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Molecular Templates","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"MT-8421","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Molecular Templates","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Molecular Templates \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Molecular Templates \/ Not Applicable"},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"CLN-617","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Cullinan Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Cullinan Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Cullinan Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Sapience Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Peptide","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"ST316","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Sapience Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Sapience Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Sapience Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Exscientia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"EXS74539","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Exscientia","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Exscientia \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Exscientia \/ Not Applicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"GRC 54276","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Glenmark Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Glenmark Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Likang Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Vaccine","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"LK101","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Likang Life Sciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Likang Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Likang Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Flare Therapeutics","sponsor":"GordonMD Global Investments","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"March 2023","year":"2023","type":"Series B Financing","leadProduct":"FX-909","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Flare Therapeutics","amount2":0.12,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.12,"dosageForm":"","sponsorNew":"Flare Therapeutics \/ GordonMD Global Investments","highestDevelopmentStatusID":"5","companyTruncated":"Flare Therapeutics \/ GordonMD Global Investments"},{"orgOrder":0,"company":"RayzeBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Peptide","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"RayzeBio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"RayzeBio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"RayzeBio \/ Not Applicable"},{"orgOrder":0,"company":"Shanghai Yingli Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"TEB-17231","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Shanghai Yingli Pharmaceutical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Shanghai Yingli Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Shanghai Yingli Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"CLN-617","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Cullinan Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Cullinan Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Cullinan Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Avacta Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"AVA3996","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Avacta Group","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Avacta Group \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Avacta Group \/ Not Applicable"},{"orgOrder":0,"company":"Acepodia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"ACE2016","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Acepodia","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Acepodia \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Acepodia \/ Not Applicable"},{"orgOrder":0,"company":"Genenta Science","sponsor":"Ospedale San Raffaele","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"April 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Genenta Science","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Genenta Science \/ Ospedale San Raffaele","highestDevelopmentStatusID":"5","companyTruncated":"Genenta Science \/ Ospedale San Raffaele"},{"orgOrder":0,"company":"Scorpion Therapeutics","sponsor":"Pierre Fabre","pharmaFlowCategory":"D","upfrontCash":"$65.0 million","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"April 2023","year":"2023","type":"Collaboration","leadProduct":"STX-721","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Scorpion Therapeutics","amount2":0.62,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.62,"dosageForm":"","sponsorNew":"Scorpion Therapeutics \/ Pierre Fabre","highestDevelopmentStatusID":"5","companyTruncated":"Scorpion Therapeutics \/ Pierre Fabre"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"April 2023","year":"2023","type":"Funding","leadProduct":"TTX-MC138","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"TransCode Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"5","companyTruncated":"TransCode Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"Tango Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"TNG260","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Tango Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Tango Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Tango Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"OncoBay Clinical","sponsor":"Hillstream BioPharma","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"April 2023","year":"2023","type":"Agreement","leadProduct":"HSB-1216","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"OncoBay Clinical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"OncoBay Clinical \/ Hillstream BioPharma","highestDevelopmentStatusID":"5","companyTruncated":"OncoBay Clinical \/ Hillstream BioPharma"},{"orgOrder":0,"company":"Hillstream BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"HSB-1216","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hillstream BioPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Hillstream BioPharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Hillstream BioPharma \/ Not Applicable"},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"[225-Actinium]-FPI-2068","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Fusion Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Fusion Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Fusion Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"LP-284","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Lantern Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Lantern Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Caris Life Sciences","sponsor":"Flare Therapeutics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"April 2023","year":"2023","type":"Partnership","leadProduct":"FX-909","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Caris Life Sciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Caris Life Sciences \/ Flare Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Caris Life Sciences \/ Flare Therapeutics"},{"orgOrder":0,"company":"Abdera Therapeutics","sponsor":"Versant Ventures","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"April 2023","year":"2023","type":"Financing","leadProduct":"ABD-147","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Abdera Therapeutics","amount2":0.14000000000000001,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.14000000000000001,"dosageForm":"","sponsorNew":"Abdera Therapeutics \/ Versant Ventures","highestDevelopmentStatusID":"5","companyTruncated":"Abdera Therapeutics \/ Versant Ventures"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Sanofi","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"April 2023","year":"2023","type":"Collaboration","leadProduct":"Evorpacept","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"ALX Oncology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ALX Oncology \/ Sanofi","highestDevelopmentStatusID":"5","companyTruncated":"ALX Oncology \/ Sanofi"},{"orgOrder":0,"company":"Hillstream BioPharma","sponsor":"ThinkEquity","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"April 2023","year":"2023","type":"Public Offering","leadProduct":"HSB-1216","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hillstream BioPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Hillstream BioPharma \/ ThinkEquity","highestDevelopmentStatusID":"5","companyTruncated":"Hillstream BioPharma \/ ThinkEquity"},{"orgOrder":0,"company":"Cartherics","sponsor":"Shunxi Holding Group","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"April 2023","year":"2023","type":"Licensing Agreement","leadProduct":"CTH-004","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Cartherics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Cartherics \/ Shunxi Holding Group","highestDevelopmentStatusID":"5","companyTruncated":"Cartherics \/ Shunxi Holding Group"},{"orgOrder":0,"company":"Hillstream BioPharma","sponsor":"ThinkEquity","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"May 2023","year":"2023","type":"Public Offering","leadProduct":"Salinomycin","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hillstream BioPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Hillstream BioPharma \/ ThinkEquity","highestDevelopmentStatusID":"5","companyTruncated":"Hillstream BioPharma \/ ThinkEquity"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"SP-3164","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Salarius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Salarius Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Defence Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"AccuTOX","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Defence Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Defence Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Defence Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"XinThera","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"May 2023","year":"2023","type":"Acquisition","leadProduct":"XIN5104","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"XinThera","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"XinThera \/ Gilead Sciences","highestDevelopmentStatusID":"5","companyTruncated":"XinThera \/ Gilead Sciences"},{"orgOrder":0,"company":"Adaptive Biotechnologies","sponsor":"Genentech","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"TCR based T-Cell Therapy","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Adaptive Biotechnologies","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Adaptive Biotechnologies \/ Genentech","highestDevelopmentStatusID":"5","companyTruncated":"Adaptive Biotechnologies \/ Genentech"},{"orgOrder":0,"company":"Hemogenyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"HEMO-CAR-T","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hemogenyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Hemogenyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Hemogenyx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Nuvectis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"NXP900","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Nuvectis Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Nuvectis Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Nuvectis Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Ocean Biomedical","sponsor":"Maxim Group LLC","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"May 2023","year":"2023","type":"Private Placement","leadProduct":"OCX-253","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ocean Biomedical","amount2":0.029999999999999999,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Ocean Biomedical \/ Maxim Group LLC","highestDevelopmentStatusID":"5","companyTruncated":"Ocean Biomedical \/ Maxim Group LLC"},{"orgOrder":0,"company":"Phio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"PH-762","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Phio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Phio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Phio Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"ImaginAb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"IAB56","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"ImaginAb","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"ImaginAb \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"ImaginAb \/ Not Applicable"},{"orgOrder":0,"company":"Trueline Therapeutics","sponsor":"Broad Institute of Harvard","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"TTX-810","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Trueline Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Trueline Therapeutics \/ Broad Institute of Harvard","highestDevelopmentStatusID":"5","companyTruncated":"Trueline Therapeutics \/ Broad Institute of Harvard"},{"orgOrder":0,"company":"Quanta Therapeutics","sponsor":"Avidity Partners","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"May 2023","year":"2023","type":"Series D Financing","leadProduct":"QTX3034","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Quanta Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Quanta Therapeutics \/ Avidity Partners","highestDevelopmentStatusID":"5","companyTruncated":"Quanta Therapeutics \/ Avidity Partners"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"AMG 193","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Ideaya Biosciences \/ Amgen Inc","highestDevelopmentStatusID":"5","companyTruncated":"Ideaya Biosciences \/ Amgen Inc"},{"orgOrder":0,"company":"OnKure Therapeutics","sponsor":"Surveyor Capital","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"May 2023","year":"2023","type":"Series C Financing","leadProduct":"OKI-219","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"OnKure Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"OnKure Therapeutics \/ Surveyor Capital","highestDevelopmentStatusID":"5","companyTruncated":"OnKure Therapeutics \/ Surveyor Capital"},{"orgOrder":0,"company":"InProTher","sponsor":"European Innovation Council","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Vaccine","date":"May 2023","year":"2023","type":"Financing","leadProduct":"IPT001","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"InProTher","amount2":0.01,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"","sponsorNew":"InProTher \/ European Innovation Council","highestDevelopmentStatusID":"5","companyTruncated":"InProTher \/ European Innovation Council"},{"orgOrder":0,"company":"BioRay Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"BRY812","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"BioRay Pharmaceutical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"BioRay Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"BioRay Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Amplia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"5-fluorouracil","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Amplia Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Amplia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Amplia Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"LTZ Therapeutics","sponsor":"Qiming Venture Partners","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","date":"May 2023","year":"2023","type":"Financing","leadProduct":"LTZ-301","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"LTZ Therapeutics","amount2":0.01,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"","sponsorNew":"LTZ Therapeutics \/ Qiming Venture Partners","highestDevelopmentStatusID":"5","companyTruncated":"LTZ Therapeutics \/ Qiming Venture Partners"},{"orgOrder":0,"company":"Tianweiyuanhe Biomedical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"A-337","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Tianweiyuanhe Biomedical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Tianweiyuanhe Biomedical \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Tianweiyuanhe Biomedical \/ Not Applicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"LP-184","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Lantern Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Lantern Pharma \/ Not Applicable"},{"orgOrder":0,"company":"TG ImmunoPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"TGI-6","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"TG ImmunoPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"TG ImmunoPharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"TG ImmunoPharma \/ Not Applicable"},{"orgOrder":0,"company":"TG ImmunoPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"TGI-6","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"TG ImmunoPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"TG ImmunoPharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"TG ImmunoPharma \/ Not Applicable"},{"orgOrder":0,"company":"Replay Bio","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"NY-ESO-1 TCR\/IL-15 NK Cell Therapy","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Replay Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Replay Bio \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"5","companyTruncated":"Replay Bio \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"LadRx","sponsor":"XOMA","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"June 2023","year":"2023","type":"Financing","leadProduct":"AE-Keto-Sulf07","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"LadRx","amount2":0.01,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"","sponsorNew":"LadRx \/ XOMA","highestDevelopmentStatusID":"5","companyTruncated":"LadRx \/ XOMA"},{"orgOrder":0,"company":"Immunome","sponsor":"Enavate Sciences","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"June 2023","year":"2023","type":"Private Placement","leadProduct":"IMM-ONC-01","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Immunome","amount2":0.13,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.13,"dosageForm":"","sponsorNew":"Immunome \/ Enavate Sciences","highestDevelopmentStatusID":"5","companyTruncated":"Immunome \/ Enavate Sciences"},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"CFT8919","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"C4 Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"C4 Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"C4 Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Poseida Therapeutics, Inc","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"P-CD19CD20-ALLO1","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Poseida Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Poseida Therapeutics, Inc \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"5","companyTruncated":"Poseida Therapeutics, Inc \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"ImPact Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Padeliporfin VTP","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"ImPact Biotech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"ImPact Biotech \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"ImPact Biotech \/ Not Applicable"},{"orgOrder":0,"company":"280Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"YL-17231","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"280Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"280Bio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"280Bio \/ Not Applicable"},{"orgOrder":0,"company":"Hemogenyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"HEMO-CAR-T","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hemogenyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Hemogenyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Hemogenyx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"SP-3164","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Salarius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Salarius Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Mabwell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"9MW2921","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Mabwell","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Mabwell \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Mabwell \/ Not Applicable"},{"orgOrder":0,"company":"Mabwell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"7MW3711","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Mabwell","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Mabwell \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Mabwell \/ Not Applicable"},{"orgOrder":0,"company":"Replay Bio","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"NY-ESO-1 TCR\/IL-15 NK Cell Therapy","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Replay Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Replay Bio \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"5","companyTruncated":"Replay Bio \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"KB707","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Krystal Biotech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Krystal Biotech \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Krystal Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Calibr","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","date":"July 2023","year":"2023","type":"Expanded Collaboration","leadProduct":"Switchable CAR T-cell Therapy","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Calibr","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Calibr \/ AbbVie Inc","highestDevelopmentStatusID":"5","companyTruncated":"Calibr \/ AbbVie Inc"},{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"QN-302","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Qualigen Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Qualigen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Qualigen Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Molecular Targeting Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"177Lu-DOTA-EB-TATE","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Molecular Targeting Technologies","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Molecular Targeting Technologies \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Molecular Targeting Technologies \/ Not Applicable"},{"orgOrder":0,"company":"BioCity Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"BC3448","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"BioCity Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"BioCity Biopharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"BioCity Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Georgiamune","sponsor":"General Catalyst","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"August 2023","year":"2023","type":"Series A Financing","leadProduct":"GIM-122","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Georgiamune","amount2":0.080000000000000002,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Georgiamune \/ General Catalyst","highestDevelopmentStatusID":"5","companyTruncated":"Georgiamune \/ General Catalyst"},{"orgOrder":0,"company":"Senti Biosciences","sponsor":"GeneFab","pharmaFlowCategory":"D","upfrontCash":"$38.0 million","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"August 2023","year":"2023","type":"Acquisition","leadProduct":"SENTI-202","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Senti Biosciences","amount2":0.040000000000000001,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Senti Biosciences \/ GeneFab","highestDevelopmentStatusID":"5","companyTruncated":"Senti Biosciences \/ GeneFab"},{"orgOrder":0,"company":"Zumutor Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"ZM008","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Zumutor Biologics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Zumutor Biologics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Zumutor Biologics \/ Not Applicable"},{"orgOrder":0,"company":"Biddle Sawyer Corporation","sponsor":"TAE Life Sciences","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"August 2023","year":"2023","type":"Agreement","leadProduct":"TC220","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Biddle Sawyer Corporation","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Biddle Sawyer Corporation \/ TAE Life Sciences","highestDevelopmentStatusID":"5","companyTruncated":"Biddle Sawyer Corporation \/ TAE Life Sciences"},{"orgOrder":0,"company":"OnCusp Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"CUSP06","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"OnCusp Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"OnCusp Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"OnCusp Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BITT","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"BITT2101","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"BITT","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"BITT \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"BITT \/ Not Applicable"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"GSK","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"IDE705","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Ideaya Biosciences \/ GSK","highestDevelopmentStatusID":"5","companyTruncated":"Ideaya Biosciences \/ GSK"},{"orgOrder":0,"company":"Alentis Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"ALE.C04","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Alentis Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Alentis Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Alentis Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"RayzeBio","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Peptide","date":"August 2023","year":"2023","type":"Public Offering","leadProduct":"Actinium-225","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"RayzeBio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"RayzeBio \/ J.P. Morgan","highestDevelopmentStatusID":"5","companyTruncated":"RayzeBio \/ J.P. Morgan"},{"orgOrder":0,"company":"Harbour BioMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"HBM9033","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Harbour BioMed","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Harbour BioMed \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Harbour BioMed \/ Not Applicable"},{"orgOrder":0,"company":"BriaPro Therapeutics","sponsor":"BriaCell Therapeutics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","date":"August 2023","year":"2023","type":"Demerger","leadProduct":"Bria-TILsRx","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"BriaPro Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"BriaPro Therapeutics \/ BriaCell Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"BriaPro Therapeutics \/ BriaCell Therapeutics"},{"orgOrder":0,"company":"InxMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"OMTX705","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"InxMed","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"InxMed \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"InxMed \/ Not Applicable"},{"orgOrder":0,"company":"TScan Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"TSC-203-A0201","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"TScan Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"TScan Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"TScan Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"KSQ Therapeutics","sponsor":"CTMC","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"September 2023","year":"2023","type":"Collaboration","leadProduct":"KSQ-001EX","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"KSQ Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"KSQ Therapeutics \/ CTMC","highestDevelopmentStatusID":"5","companyTruncated":"KSQ Therapeutics \/ CTMC"},{"orgOrder":0,"company":"Tango Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Olaparib","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Tango Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Tango Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Tango Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Carrick Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"CT7439","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Carrick Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Carrick Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Carrick Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Actimed Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"S-pindolol Benzoate","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Actimed Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Actimed Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Actimed Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Medivir","sponsor":"Tango Therapeutics","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"TNG348","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Medivir \/ Tango Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Medivir \/ Tango Therapeutics"},{"orgOrder":0,"company":"BioSyngen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"BRL03","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"BioSyngen","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioSyngen \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"BioSyngen \/ Not Applicable"},{"orgOrder":0,"company":"Insilico Medicine","sponsor":"Exelixis","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"September 2023","year":"2023","type":"Licensing Agreement","leadProduct":"ISM3091","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Insilico Medicine","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Insilico Medicine \/ Exelixis","highestDevelopmentStatusID":"5","companyTruncated":"Insilico Medicine \/ Exelixis"},{"orgOrder":0,"company":"Vertical bio","sponsor":"Pierre Fabre","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Large molecule","date":"September 2023","year":"2023","type":"Acquisition","leadProduct":"VERT-002","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Vertical bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Vertical bio \/ Pierre Fabre","highestDevelopmentStatusID":"5","companyTruncated":"Vertical bio \/ Pierre Fabre"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Furmonertinib","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"InnoCare Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"InnoCare Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"LP-284","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Lantern Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Lantern Pharma \/ Not Applicable"},{"orgOrder":0,"company":"GigaGen","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"September 2023","year":"2023","type":"Agreement","leadProduct":"GIGA-564","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"GigaGen","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"GigaGen \/ National Cancer Institute","highestDevelopmentStatusID":"5","companyTruncated":"GigaGen \/ National Cancer Institute"},{"orgOrder":0,"company":"GEDiCube","sponsor":"Renovaro Biosciences","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Vaccine","date":"September 2023","year":"2023","type":"Merger","leadProduct":"Dendritic Cell Therapeutic Vaccine","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"GEDiCube","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"GEDiCube \/ Renovaro Biosciences","highestDevelopmentStatusID":"5","companyTruncated":"GEDiCube \/ Renovaro Biosciences"},{"orgOrder":0,"company":"Immunome","sponsor":"Enavate Sciences","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"October 2023","year":"2023","type":"Private Placement","leadProduct":"IMM20320","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Immunome","amount2":0.13,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.13,"dosageForm":"","sponsorNew":"Immunome \/ Enavate Sciences","highestDevelopmentStatusID":"5","companyTruncated":"Immunome \/ Enavate Sciences"},{"orgOrder":0,"company":"Iambic Therapeutics","sponsor":"Ascenta Capital","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"October 2023","year":"2023","type":"Series B Financing","leadProduct":"IAM-H1","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Iambic Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Iambic Therapeutics \/ Ascenta Capital","highestDevelopmentStatusID":"5","companyTruncated":"Iambic Therapeutics \/ Ascenta Capital"},{"orgOrder":0,"company":"Radiopharm Theranostics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"RAD204","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Radiopharm Theranostics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Radiopharm Theranostics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Radiopharm Theranostics \/ Not Applicable"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"GSK","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"October 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ideaya Biosciences","amount2":0.95999999999999996,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.95999999999999996,"dosageForm":"","sponsorNew":"Ideaya Biosciences \/ GSK","highestDevelopmentStatusID":"5","companyTruncated":"Ideaya Biosciences \/ GSK"},{"orgOrder":0,"company":"Actym Therapeutics","sponsor":"Boehringer Ingelheim Venture Fund","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"October 2023","year":"2023","type":"Series A Financing","leadProduct":"ACTM-838","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Actym Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Actym Therapeutics \/ Boehringer Ingelheim Venture Fund","highestDevelopmentStatusID":"5","companyTruncated":"Actym Therapeutics \/ Boehringer Ingelheim Venture Fund"},{"orgOrder":0,"company":"Flare Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"3-(5,7-difluoro-4-oxo-1H-quinolin-2-yl)-4-methylsulfonylbenzonitrile","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Flare Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Flare Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Flare Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"AGC Biologics","sponsor":"Medigene","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"October 2023","year":"2023","type":"Agreement","leadProduct":"MDG1015","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"AGC Biologics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"AGC Biologics \/ Medigene","highestDevelopmentStatusID":"5","companyTruncated":"AGC Biologics \/ Medigene"},{"orgOrder":0,"company":"Engine Biosciences","sponsor":"Polaris Partners","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"October 2023","year":"2023","type":"Series A Financing","leadProduct":"ENB-812","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Engine Biosciences","amount2":0.089999999999999997,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Engine Biosciences \/ Polaris Partners","highestDevelopmentStatusID":"5","companyTruncated":"Engine Biosciences \/ Polaris Partners"},{"orgOrder":0,"company":"Ensem Therapeutics","sponsor":"BeiGene","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"November 2023","year":"2023","type":"Licensing Agreement","leadProduct":"ETX-197","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ensem Therapeutics","amount2":1.3300000000000001,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":1.3300000000000001,"dosageForm":"","sponsorNew":"Ensem Therapeutics \/ BeiGene","highestDevelopmentStatusID":"5","companyTruncated":"Ensem Therapeutics \/ BeiGene"},{"orgOrder":0,"company":"KaliVir Immunotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Vaccine","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"ASP1012","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"KaliVir Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"KaliVir Immunotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"KaliVir Immunotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BioRay Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"BR105","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"BioRay Pharmaceutical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioRay Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"BioRay Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Seed Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"ST-00937","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Seed Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Seed Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Seed Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Vittoria Biotherapeutics","sponsor":"Valley Forge Investment Corporation","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"November 2023","year":"2023","type":"Private Placement","leadProduct":"VIPER-101","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Vittoria Biotherapeutics","amount2":0.02,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"","sponsorNew":"Vittoria Biotherapeutics \/ Valley Forge Investment Corporation","highestDevelopmentStatusID":"5","companyTruncated":"Vittoria Biotherapeutics \/ Valley Forge Investment Corporation"},{"orgOrder":0,"company":"BioSyngen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"BST02","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"BioSyngen","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"BioSyngen \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"BioSyngen \/ Not Applicable"},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"RP-1664","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Repare Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Repare Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Repare Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"November 2023","year":"2023","type":"Public Offering","leadProduct":"TTX-MC138","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"TransCode Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"5","companyTruncated":"TransCode Therapeutics \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Angiex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"AGX 101","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Angiex","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Angiex \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Angiex \/ Not Applicable"},{"orgOrder":0,"company":"Context Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"CTIM-76","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Context Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Context Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Context Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","upfrontCash":"$53.0 million","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"December 2023","year":"2023","type":"Licensing Agreement","leadProduct":"HBM9033","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Nona Biosciences","amount2":1.1000000000000001,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":1.1000000000000001,"dosageForm":"","sponsorNew":"Nona Biosciences \/ Pfizer Inc","highestDevelopmentStatusID":"5","companyTruncated":"Nona Biosciences \/ Pfizer Inc"},{"orgOrder":0,"company":"Miltenyi Biotec","sponsor":"Syena","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"December 2023","year":"2023","type":"Licensing Agreement","leadProduct":"SY-001","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Miltenyi Biotec","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Miltenyi Biotec \/ Syena","highestDevelopmentStatusID":"5","companyTruncated":"Miltenyi Biotec \/ Syena"},{"orgOrder":0,"company":"Miltenyi Biotec","sponsor":"Cell BioEngines","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"December 2023","year":"2023","type":"Agreement","leadProduct":"CBE-101","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Miltenyi Biotec","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Miltenyi Biotec \/ Cell BioEngines","highestDevelopmentStatusID":"5","companyTruncated":"Miltenyi Biotec \/ Cell BioEngines"},{"orgOrder":0,"company":"MediLink Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","upfrontCash":"$50.0 million","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"January 2024","year":"2024","type":"Collaboration","leadProduct":"YL211","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"MediLink Therapeutics","amount2":1,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":1,"dosageForm":"","sponsorNew":"MediLink Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"5","companyTruncated":"MediLink Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Pasithea Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"CIP-137401","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Pasithea Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Pasithea Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Pasithea Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Compugen","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","upfrontCash":"$60.0 million","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"December 2023","year":"2023","type":"Licensing Agreement","leadProduct":"COM503","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Compugen","amount2":0.84999999999999998,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.84999999999999998,"dosageForm":"","sponsorNew":"Compugen \/ Gilead Sciences","highestDevelopmentStatusID":"5","companyTruncated":"Compugen \/ Gilead Sciences"},{"orgOrder":0,"company":"OnKure Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"OKI-219","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"OnKure Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"OnKure Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"OnKure Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Quanta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"QTX3034","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Quanta Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Quanta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Quanta Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Senti Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"SENTI-202","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Senti Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Senti Biosciences \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Senti Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"SC262","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Sana Biotechnology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Sana Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Sana Biotechnology \/ Not Applicable"},{"orgOrder":0,"company":"Nuvation Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"NUV-1511","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Nuvation Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Nuvation Bio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Nuvation Bio \/ Not Applicable"},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"CRB-601","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Corbus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Corbus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Corbus Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Focal Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Gemcitabine","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Focal Medical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Focal Medical \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Focal Medical \/ Not Applicable"},{"orgOrder":0,"company":"OBI Pharma","sponsor":"Biosion","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"OBI-992","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"OBI Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"OBI Pharma \/ Biosion","highestDevelopmentStatusID":"5","companyTruncated":"OBI Pharma \/ Biosion"},{"orgOrder":0,"company":"Insilico Medicine","sponsor":"Stemline Therapeutics","pharmaFlowCategory":"D","upfrontCash":"$12.0 million","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"January 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Insilico Medicine","amount2":0.51000000000000001,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.51000000000000001,"dosageForm":"","sponsorNew":"Insilico Medicine \/ Stemline Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Insilico Medicine \/ Stemline Therapeutics"},{"orgOrder":0,"company":"OnCusp Therapeutics","sponsor":"Novo Holdings","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"January 2024","year":"2024","type":"Series A Financing","leadProduct":"CUSP06","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"OnCusp Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"OnCusp Therapeutics \/ Novo Holdings","highestDevelopmentStatusID":"5","companyTruncated":"OnCusp Therapeutics \/ Novo Holdings"},{"orgOrder":0,"company":"OBI Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"OBI-992","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"OBI Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"OBI Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"OBI Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Presage Biosciences","sponsor":"Pure Biologics","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"PBA-0405","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Presage Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Presage Biosciences \/ Pure Biologics","highestDevelopmentStatusID":"5","companyTruncated":"Presage Biosciences \/ Pure Biologics"},{"orgOrder":0,"company":"Amplia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"AMP945","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Amplia Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Amplia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Amplia Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Lava Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"January 2024","year":"2024","type":"Collaboration","leadProduct":"LAVA-1207","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lava Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lava Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"5","companyTruncated":"Lava Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"CDR Life","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"CDR404","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"CDR Life","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"CDR Life \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"CDR Life \/ Not Applicable"},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"CRB-601","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Corbus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Corbus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Corbus Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"HEPHAISTOS-Pharma","sponsor":"Xista Science Ventures","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","date":"January 2024","year":"2024","type":"Financing","leadProduct":"ONCO-Boost","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"HEPHAISTOS-Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"HEPHAISTOS-Pharma \/ Xista Science Ventures","highestDevelopmentStatusID":"5","companyTruncated":"HEPHAISTOS-Pharma \/ Xista Science Ventures"},{"orgOrder":0,"company":"Acepodia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"ACE2016","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Acepodia","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Acepodia \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Acepodia \/ Not Applicable"},{"orgOrder":0,"company":"Hemogenyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"HEMO-CAR-T","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hemogenyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Hemogenyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Hemogenyx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"NK CellTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"NK010","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"NK CellTech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"NK CellTech \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"NK CellTech \/ Not Applicable"},{"orgOrder":0,"company":"Aprea Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"APR-1051","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Aprea Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Aprea Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Aprea Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Vaccine","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"BriaCell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"BriaCell Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"European Commission","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"June 2022","year":"2022","type":"Funding","leadProduct":"Iadademstat","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Oryzon Genomics \/ European Commission","highestDevelopmentStatusID":"5","companyTruncated":"Oryzon Genomics \/ European Commission"},{"orgOrder":0,"company":"Immune-Onc Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"February 2024","year":"2024","type":"Collaboration","leadProduct":"Atezolizumab","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Immune-Onc Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Immune-Onc Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"5","companyTruncated":"Immune-Onc Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Immunofoco","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"IMC001","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Immunofoco","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immunofoco \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Immunofoco \/ Not Applicable"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"North Star Processing, LLC.","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"MNPR-101-Zr","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Monopar Therapeutics \/ North Star Processing, LLC","highestDevelopmentStatusID":"5","companyTruncated":"Monopar Therapeutics \/ North Star Processing, LLC"},{"orgOrder":0,"company":"Exelixis","sponsor":"Arcus Biosciences","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"December 2023","year":"2023","type":"Collaboration","leadProduct":"Encoberminogene Rezmadenovec","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Exelixis \/ Arcus Biosciences","highestDevelopmentStatusID":"5","companyTruncated":"Exelixis \/ Arcus Biosciences"},{"orgOrder":0,"company":"Aprea Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"APR-1051","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Aprea Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Aprea Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Aprea Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Emendo Biotherapeutics","sponsor":"Anocca","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"March 2024","year":"2024","type":"Licensing Agreement","leadProduct":"TCR-T Therapy","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Emendo Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Emendo Biotherapeutics \/ Anocca","highestDevelopmentStatusID":"5","companyTruncated":"Emendo Biotherapeutics \/ Anocca"},{"orgOrder":0,"company":"Aptamer Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"AST-201","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Aptamer Group","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Aptamer Group \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Aptamer Group \/ Not Applicable"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Nadunolimab","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cantargia AB \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Cantargia AB \/ Not Applicable"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Equecabtagene Autoleucel","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IASO Bio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"IASO Bio \/ Not Applicable"},{"orgOrder":0,"company":"Theseus Pharmaceuticals","sponsor":"Concentra Biosciences","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","date":"December 2023","year":"2023","type":"Acquisition","leadProduct":"THE-349","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Theseus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Theseus Pharmaceuticals \/ Concentra Biosciences","highestDevelopmentStatusID":"5","companyTruncated":"Theseus Pharmaceuticals \/ Concentra Biosciences"},{"orgOrder":0,"company":"Theseus Pharmaceuticals","sponsor":"Concentra Biosciences","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"February 2024","year":"2024","type":"Acquisition","leadProduct":"THE-349","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Theseus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Theseus Pharmaceuticals \/ Concentra Biosciences","highestDevelopmentStatusID":"5","companyTruncated":"Theseus Pharmaceuticals \/ Concentra Biosciences"},{"orgOrder":0,"company":"Accent Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"January 2024","year":"2024","type":"Series C Financing","leadProduct":"ATX968","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Accent Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Accent Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"5","companyTruncated":"Accent Therapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Umoja Biopharma","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"January 2024","year":"2024","type":"Collaboration","leadProduct":"UB-VV111","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Umoja Biopharma","amount2":1.4399999999999999,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":1.4399999999999999,"dosageForm":"","sponsorNew":"Umoja Biopharma \/ AbbVie Inc","highestDevelopmentStatusID":"5","companyTruncated":"Umoja Biopharma \/ AbbVie Inc"},{"orgOrder":0,"company":"Aprea Therapeutics","sponsor":"Maxim Group LLC","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"March 2024","year":"2024","type":"Private Placement","leadProduct":"APR-1051","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Aprea Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Aprea Therapeutics \/ Maxim Group LLC","highestDevelopmentStatusID":"5","companyTruncated":"Aprea Therapeutics \/ Maxim Group LLC"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Merck & Co","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"March 2024","year":"2024","type":"Collaboration","leadProduct":"IDE161","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Ideaya Biosciences \/ Merck & Co","highestDevelopmentStatusID":"5","companyTruncated":"Ideaya Biosciences \/ Merck & Co"},{"orgOrder":0,"company":"Chimeric Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"CHM 2101","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Chimeric Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Chimeric Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Chimeric Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"KSQ Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"KSQ-001EX","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"KSQ Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"KSQ Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"KSQ Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"GT Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"GTB-3650","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"GT Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"GT Biopharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"GT Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"CV6 Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"5-Fluorouracil","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"CV6 Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"CV6 Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"CV6 Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Kronos Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"KB-9558","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Kronos Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Kronos Bio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Kronos Bio \/ Not Applicable"},{"orgOrder":0,"company":"Avstera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"AVS100","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Avstera Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Avstera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Avstera Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"NeuExcell therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"NXL-004","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"NeuExcell therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"NeuExcell therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"NeuExcell therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Ariceum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"ATT001","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ariceum Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Ariceum Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Ariceum Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Cellectar","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"225Ac-CLR 121225","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Cellectar","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Cellectar \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Cellectar \/ Not Applicable"},{"orgOrder":0,"company":"Kurome Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"KME-0584","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Kurome Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Kurome Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Kurome Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Mestag Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"M300","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Mestag Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Mestag Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Mestag Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Ariceum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"ATT001","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ariceum Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Ariceum Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Ariceum Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"CLN-619","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Cullinan Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cullinan Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Cullinan Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"JAB-30300","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Jacobio Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Jacobio Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Jacobio Pharma \/ Not Applicable"},{"orgOrder":0,"company":"PhotonPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Vaccine","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Personalized Vaccine Therapy","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"PhotonPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"PhotonPharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"PhotonPharma \/ Not Applicable"},{"orgOrder":0,"company":"CERo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"CER-1236","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"CERo Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"CERo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"CERo Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Eilean Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Balamenib","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Eilean Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Eilean Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Eilean Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"ICP-248","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"InnoCare Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"InnoCare Pharma \/ Not Applicable"},{"orgOrder":0,"company":"858 Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"ETX-19477","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"858 Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"858 Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"858 Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"HDT Biotech","sponsor":"BARDA","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Vaccine","date":"January 2024","year":"2024","type":"Partnership","leadProduct":"HDT-521","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"HDT Biotech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"HDT Biotech \/ BARDA","highestDevelopmentStatusID":"5","companyTruncated":"HDT Biotech \/ BARDA"},{"orgOrder":0,"company":"Kintara Therapeutics","sponsor":"TuHURA Biosciences","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Vaccine","date":"April 2024","year":"2024","type":"Merger","leadProduct":"IFx-2.0","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Kintara Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Injection","sponsorNew":"Kintara Therapeutics \/ TuHURA Biosciences","highestDevelopmentStatusID":"5","companyTruncated":"Kintara Therapeutics \/ TuHURA Biosciences"},{"orgOrder":0,"company":"Carisma Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"CT-0525","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Carisma Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Carisma Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Carisma Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Pasithea Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"PAS-004","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Pasithea Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Pasithea Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Pasithea Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Vittoria Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"VIPER-101","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Vittoria Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Vittoria Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Vittoria Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"NextPoint","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"NPX887","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"NextPoint","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NextPoint \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"NextPoint \/ Not Applicable"},{"orgOrder":0,"company":"GigaGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"GIGA-564","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"GigaGen","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"GigaGen \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"GigaGen \/ Not Applicable"},{"orgOrder":0,"company":"SIRPant Immunotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"SI-101","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"SIRPant Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"SIRPant Immunotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"SIRPant Immunotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Senti Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"SENTI-202","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Senti Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Senti Biosciences \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Senti Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Context Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"CTIM-76","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Context Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Context Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Context Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Alterome Therapeutics","sponsor":"Goldman Sachs","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"April 2024","year":"2024","type":"Series B Financing","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Alterome Therapeutics","amount2":0.13,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.13,"dosageForm":"","sponsorNew":"Alterome Therapeutics \/ Goldman Sachs","highestDevelopmentStatusID":"5","companyTruncated":"Alterome Therapeutics \/ Goldman Sachs"},{"orgOrder":0,"company":"Lamassu Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"SA53-OS","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lamassu Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Lamassu Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Lamassu Pharma \/ Not Applicable"},{"orgOrder":0,"company":"BioCity Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"BC2027","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"BioCity Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"BioCity Biopharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"BioCity Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Neuboron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"P-Borono-L-Phenylalanine","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Neuboron","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Neuboron \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Neuboron \/ Not Applicable"},{"orgOrder":0,"company":"Calidi Biotherapeutics","sponsor":"Ladenburg Thalmann","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"April 2024","year":"2024","type":"Public Offering","leadProduct":"CLD-101","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Calidi Biotherapeutics","amount2":0.01,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"","sponsorNew":"Calidi Biotherapeutics \/ Ladenburg Thalmann","highestDevelopmentStatusID":"5","companyTruncated":"Calidi Biotherapeutics \/ Ladenburg Thalmann"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"United States Department of Defense","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"April 2024","year":"2024","type":"Funding","leadProduct":"Rhenium-186 Obisbemeda","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Plus Therapeutics \/ United States Department of Defense","highestDevelopmentStatusID":"5","companyTruncated":"Plus Therapeutics \/ United States Department of Defense"},{"orgOrder":0,"company":"Hanmi Pharmaceutical","sponsor":"Merck & Co","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"April 2024","year":"2024","type":"Collaboration","leadProduct":"BH3120","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hanmi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Hanmi Pharmaceutical \/ Merck & Co","highestDevelopmentStatusID":"5","companyTruncated":"Hanmi Pharmaceutical \/ Merck & Co"},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Vaccine","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"HB-700","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hookipa Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Hookipa Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Hookipa Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","upfrontCash":"$25.0 million","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"May 2024","year":"2024","type":"Collaboration","leadProduct":"Alpha-beta T Cell Therapy","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Editas Medicine","amount2":3.8900000000000001,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":3.8900000000000001,"dosageForm":"","sponsorNew":"Editas Medicine \/ Bristol Myers Squibb","highestDevelopmentStatusID":"5","companyTruncated":"Editas Medicine \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Serum Institute of India","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"May 2024","year":"2024","type":"Agreement","leadProduct":"Nogapendekin Alfa Inbakicept","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"ImmunityBio \/ Serum Institute of India","highestDevelopmentStatusID":"5","companyTruncated":"ImmunityBio \/ Serum Institute of India"},{"orgOrder":0,"company":"Replay Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Decitabine","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Replay Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Replay Bio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Replay Bio \/ Not Applicable"},{"orgOrder":0,"company":"Context Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"CTIM-76","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Context Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Context Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Context Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BioAtla","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"BA3361","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"BioAtla","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"BioAtla \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"BioAtla \/ Not Applicable"},{"orgOrder":0,"company":"Eisbach Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"EIS-12656","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Eisbach Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Eisbach Bio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Eisbach Bio \/ Not Applicable"},{"orgOrder":0,"company":"BioTheryX","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"BTX-9341","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"BioTheryX","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"BioTheryX \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"BioTheryX \/ Not Applicable"},{"orgOrder":0,"company":"Chengdu Weisijin Biomedical Technology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Vaccine","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"WGc-043","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Chengdu Weisijin Biomedical Technology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Chengdu Weisijin Biomedical Technology \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Chengdu Weisijin Biomedical Technology \/ Not Applicable"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"PFL-002","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Pierre Fabre \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Pierre Fabre \/ Not Applicable"},{"orgOrder":0,"company":"Adicet Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"ADI-270","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Adicet Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Adicet Bio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Adicet Bio \/ Not Applicable"},{"orgOrder":0,"company":"BlueSphere Bio","sponsor":"NMDP BioTherapies","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"June 2024","year":"2024","type":"Partnership","leadProduct":"BSB-1001","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"BlueSphere Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"BlueSphere Bio \/ NMDP BioTherapies","highestDevelopmentStatusID":"5","companyTruncated":"BlueSphere Bio \/ NMDP BioTherapies"},{"orgOrder":0,"company":"BlueSphere Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"BSB-1001","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"BlueSphere Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"BlueSphere Bio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"BlueSphere Bio \/ Not Applicable"},{"orgOrder":0,"company":"CSPC Pharmaceutical Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"mRNA-Lipid Nanoparticles","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"CSPC Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"CSPC Pharmaceutical Group \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"CSPC Pharmaceutical Group \/ Not Applicable"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"RD118","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"IASO Bio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"IASO Bio \/ Not Applicable"},{"orgOrder":0,"company":"SCG Cell Therapy","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"SCG142","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"SCG Cell Therapy","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"SCG Cell Therapy \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"SCG Cell Therapy \/ Not Applicable"},{"orgOrder":0,"company":"Abdera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Actinium-225","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Abdera Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Abdera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Abdera Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Abdera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Actinium-225","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Abdera Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Abdera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Abdera Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Anaveon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"ANV600","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Anaveon","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Anaveon \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Anaveon \/ Not Applicable"},{"orgOrder":0,"company":"Bright Peak Therapeutics","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"June 2024","year":"2024","type":"Series C Financing","leadProduct":"BPT567","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Bright Peak Therapeutics","amount2":0.089999999999999997,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Bright Peak Therapeutics \/ Johnson & Johnson","highestDevelopmentStatusID":"5","companyTruncated":"Bright Peak Therapeutics \/ Johnson & Johnson"},{"orgOrder":0,"company":"FibroGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"FG-3165","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"FibroGen \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"FibroGen \/ Not Applicable"},{"orgOrder":0,"company":"GT Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"GTB-3650","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"GT Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"GT Biopharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"GT Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Zymeworks","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Large molecule","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"ZW171","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Zymeworks","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Zymeworks \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Zymeworks \/ Not Applicable"},{"orgOrder":0,"company":"Full-Life Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"225Ac-FL-020","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Full-Life Technologies","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Full-Life Technologies \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Full-Life Technologies \/ Not Applicable"},{"orgOrder":0,"company":"Avelos Therapeutics","sponsor":"Stassets Investment","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"May 2024","year":"2024","type":"Series B Financing","leadProduct":"AD1208","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Avelos Therapeutics","amount2":0.01,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"","sponsorNew":"Avelos Therapeutics \/ Stassets Investment","highestDevelopmentStatusID":"5","companyTruncated":"Avelos Therapeutics \/ Stassets Investment"},{"orgOrder":0,"company":"Hinova","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"HP518","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hinova","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Hinova \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Hinova \/ Not Applicable"},{"orgOrder":0,"company":"GenFleet Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"VS-7375","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"GenFleet Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"GenFleet Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"GenFleet Therapeutics \/ Not Applicable"}]
Find FDA Investigational New Drug (IND) Submissions for Oncology
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
